Antiviral compounds against rsv, their use and pharmaceutical composition comprising them

专利摘要:
ANTIVIRAL COMPOUNDS AGAINST RSV. The present invention relates to inhibitors of RSV replication of the formula RI Formula (RI) including stereochemically isomeric forms thereof, and salts or solvates, wherein R 22 , W, Q, V, Z, p, s, and Het have the meaning as defined here. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing the same and their use, alone or in combination with other RSV inhibitors, in therapy against RSV.
公开号:BR112015008325B1
申请号:R112015008325-0
申请日:2013-10-15
公开日:2022-01-25
发明作者:Abdellah Tahri；Sandrine Marie Helene Vendeville；Lili Hu；Samuël Dominique Demin；Ludwig Paul Cooymans；Tim Hugo Maria Jonckers；Pierre Jean-Marie Bernard Raboisson
申请人:Janssen Sciences Ireland Uc；
IPC主号:

专利说明:

Field of Invention
[001] The present invention relates to novel spiro compounds having antiviral activity, in particular, having an inhibitory activity on respiratory syncytial virus (RSV) replication. The invention further relates to the preparation of such novel compounds, compositions comprising these compounds, and compounds for use in the treatment of respiratory syncytial virus infection. background
[002] RSV or human Respiratory Syncytial Virus is a large RNA virus, a member of the Paramyxoviridae family, pneumoviridae subfamily together with the Bovine Respiratory Syncytial Virus. Human RSV is responsible for a spectrum of respiratory tract diseases in people of all ages around the world. It is the leading cause of lower respiratory tract disease during infancy and childhood. More than half of all infants encounter RSV within their first year of life, and nearly all within their first two years. Infection in young children can cause lung damage that persists for years and can contribute to chronic lung disease later in life (chronic wheezing, asthma). Older children and adults often suffer from a common (bad) cold following RSV infection. In old age, susceptibility increases again, and RSV has been implicated in a number of outbreaks of pneumonia in the elderly resulting in significant mortality.
[003] Infection with a virus from a given subgroup does not protect against a subsequent infection with an RSV isolate from the same subgroup in the next winter season. Reinfection with RSV is thus common, despite the existence of only two subtypes, A and B.
[004] Today, only three drugs have been approved for use against RSV infection. A first is ribavirin, a nucleoside analogue that provides an aerosol treatment for severe RSV infection in hospitalized children. The aerosol route of administration, toxicity (rich in teratogenicity), cost and highly variable effectiveness limit its use. The other two drugs, RespiGam® (RSV-IG) and Synagis® (palivizumab), both polyclonal and monoclonal antibody immunostimulators, are intended to be used in a preventive manner. Both are very expensive, and require parenteral administration.
[005] Other attempts to develop a safe and effective vaccine against RSV have all failed so far. Inactivated vaccines failed to protect against disease, and indeed in some cases intensified the disease during subsequent infection. Live attenuated vaccines have been tried with limited success. Clearly there is a need for a non-toxic and easy to administer drug effective against RSV replication. It would be particularly preferred to provide drugs against RSV replication that could be administered perorally.
[006] A reference on structure-activity relationships, with respect to RSV inhibition, of 5-substituted benzimidazole compounds is X. A. Wang et al., Bioorganic and Medicinal Chemistry Letters 17 (2007) 4592-4598.
[007] Compounds that exhibit anti-RSV activity are described in WO2012/080446, WO2012/080447, WO2012/080449, WO2012/080450 and WO2012/080451.
[008] WO-2004/069256 describes 2-cyanopyrrolopyrimidines and WO-2004/076455 describes spiro substituted 2-cyanopyrrolopyrimidines as cathepsin K or S inhibitors useful in the treatment of various pain disorders. Teno N. et al. in Bioorganic & Medicinal Chemistry Letters, vol. 17, 6096 - 6100 (2007) and Teno N. et al. in J Med. Chem., vol. 51, 5459 - 5462 (2008) describe 2-cyanopyrrolopyrimidines as cathepsin K inhibitors.
[009] Potential problems that RSV antivirals may encounter are toxicity, mutagenicity, lack of selectivity, poor efficacy, poor bioavailability, and difficulty of synthesis.
[0010] Whether to provide new compounds that have antiviral activity. Particularly, it would be desirable to provide new drugs that have inhibitory activity on RSV replication. Additionally, it would be desired to recover structures of compounds that allow obtaining antiviral biological activities of the order of magnitude in the strongest regions of the prior art, and preferably at a level of about the most active compounds, most preferably of even stronger activity, than compounds described in the art. An additional desire is to find compounds having oral antiviral activity.
[0011] There is a need for additional RSV inhibitors that can overcome at least one of these disadvantages or have one of the desired effects. Summary of the Invention
[0012] In order to better fulfill one or more of the aforementioned wishes, the invention, in one aspect, features antiviral compounds represented by Formula (RI),
or any stereoisomeric form thereof, wherein: Het is a heterocycle of any of the following formulas (a), (b), (c), (d):
each X is independently C or N; provided that at least two X's are C; each of R1a, R1b, R1c or R1d is independently selected from the group consisting of H, halogen, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 alkyloxy, N(R6)2, CO(R7), CH2NH2, CH2OH , CN, C(=NOH)NH2 , C(=NOCH3 )NH2 , C(=NH)NH2 , CF3 and OCF3; R1b or R1d is absent when the X to which it is attached is N; each R2 is -(CR8R9)m-R10; m is an integer from 0 to 6; each R3 is independently selected from the group consisting of H, halogen, aryl, heteroaryl, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 alkyloxy and CO(R7); each R6 is independently selected from the group consisting of H, C1-C6 alkyl, COOCH3 and CONHSO2CH3; each R7 is independently selected from the group consisting of H, C1-C6 alkyl, OH, C1-C6 alkyloxy, NH2, NHSO2N(C1-C6 alkyl)2, NHSO2NHCH3, NHSO2(C1-C6 alkyl), NHSO2(C3-C7 cycloalkyl) ) and N(C1-C6-alkyl)2 NR8R9 and NR9R10; each R8 and R9 is independently selected from the group consisting of H, C1-C10 alkyl and C3-C7 cycloalkyl; or R8 and R9 taken together form a 4- to 6-membered saturated ring optionally containing one or more heteroatoms selected from the group consisting of N, S and O; each R10 is independently selected from the group consisting of H, halogen, OH, CN, CF2H, CF3, C1-C6 alkyl, C3-C7 cycloalkyl, C(=O)C1-C6 alkyl, C(=O)C3-C7 cycloalkyl , C(=O)NR8R9, C(=O)OR8, 8 8 9 8 89 89 SO2R , C(=O)N(R )SO2R , C(=O)N(R )SO2N(RR ), NR R , 8 9 8 8 9 89 8 NR C(=O)OR , OC(=O)R , O-benzyl, NR SO2R , SO2NR R , SO2R , 8 9 8 12 8 8 9 11 OC(=O)NR R , OC(=O)NR R , N(R )C(=O)N(RR ), R , N(R8)C(=O)OR12, OR11, C(=O)R11 and a ring saturated with 4 the 6-membered one containing an oxygen atom; R11 is phenyl, pyridinyl or pyrazolyl; each of which may optionally be substituted by one or more substituents, each independently selected from the group consisting of CF3, CH3, OCH3, OCF3 and halogen; R12 is C1-C6 alkyl or C3-C7 cycloalkyl; each substituted by one or more substituents, each independently selected from the group consisting of CF3, CH3, OCH3, OCF3 and halogen; each Z is independently C or N, provided that at least two Z are C; Q and V independently each represent C=O, SO2, or pes independently represent an integer from 0 to 3, where the sum of pes must be at least 2, and when p = 0 or s = 0, then the carbon atom marked with * is directly linked to W; R20 and R21 are independently selected from the group consisting of hydrogen, hydroxyl, C1-C3 alkyl, C3-C7 cycloalkyl, CF3, OCH3, OCF3 and halogen; R22 is selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C3-C7 cycloalkyl, CF3, OCH3, OCF3 and halogen; W is selected from the group consisting of SO, SO2 , S, C, O and N, wherein such C or N is optionally substituted by one or more R23 ; R23 is selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6-R24 alkyl, SO2R24, SO2N(R24)2, aryl, heteroaryl, C(=O)OR24, OR24 , C(=O)R24, C(=O)N(R24 )2, OC(=O)N(R24 )2, P(=O)-(O-C1-C6-alkyl)2, N(R24 )2, NR25C(=O)OR24, NR25C(=O)N(R24)2, NR25SO2R24 and a 4 to 6 membered saturated ring containing an oxygen atom, wherein any such C1-C6 alkyl, C3 cycloalkyl -C7, aryl or heteroaryl is optionally substituted by one or more of the substituents selected from the group consisting of halogen, OH, CN, OCH3; R24 is selected from the group of hydrogen, OH, halogen, C1C6 alkyl, C3-C7 cycloalkyl, C(=O) C1-C6 alkyl, C(=O) C3-C7 cycloalkyl, aryl, heteroaryl, benzyl, and a saturated ring 4 to 6 membered containing an oxygen atom, wherein any of such C1C6 alkyl, C3-C7 cycloalkyl, C(=O) C1-C6 alkyl, C(=O) C3-C7 cycloalkyl, aryl, heteroaryl, benzyl is optionally substituted by one or more of the substituents selected from the group consisting of halogen, CF3, OH, CN, OCH3,OC(=O)CH3 and C1-C3 alkyl substituted by at least one CN; R25 is selected from the group consisting of hydrogen and C1-C3 alkyl; aryl represents phenyl or naphthalenyl; heteroaryl represents a monocyclic 5- to 6-membered aromatic heterocycle containing one or more heteroatoms, each independently selected from the group consisting of O, S and N; or a bicyclic 8- to 12-membered aromatic heterocycle containing one or more heteroatoms, each independently selected from the group consisting of O, S and N; provided that Het does not satisfy a formula d(x)
or a pharmaceutically acceptable addition salt or solvate thereof.
[0013] Preferably, R23 is selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 alkyl-R24, SO2R24, SO2N(R24)2, aryl, heteroaryl, C(=O) OR24, OR24, C(=O)R24, C(=O)N(R24 )2, OC(=O)N(R24 )2 and a 4 to 6 membered saturated ring containing an oxygen atom, where any one of such C1-C6 alkyl, C3-C7 cycloalkyl, aryl or heteroaryl is optionally substituted by one or more of the substituents selected from the group consisting of halogen, OH, CN, OCH3;
[0014] R24 is selected from the group of hydrogen, OH, halogen, C1-C6 alkyl, C3-C7 cycloalkyl, C(=O) C1-C6 alkyl, C(=O) C3-C7 cycloalkyl, aryl, heteroaryl , benzyl, and a 4 to 6 membered saturated ring containing an oxygen atom, wherein any such C1-C6 alkyl, C3-C7 cycloalkyl, C(=O) C1-C6 alkyl, C(=O) cycloal - C3-C7 alkyl, aryl, heteroaryl, benzyl is optionally substituted by one or more of the substituents selected from the group consisting of halogen, CF3, OH, CN, OCH3, and OC(=O)CH3.
[0015] In another aspect, the invention relates to the aforementioned compounds for use in treating RSV infections in warm-blooded animals, preferably humans. In yet another aspect, the invention features a method of treating RSV viral infections in a subject in need thereof, comprising administering to said subject an effective amount of a compound as defined above. In yet another aspect, the invention resides in the use of a compound as defined above, for the manufacture of a medicament for the treatment of RSV infections.
[0016] In a further aspect, the invention relates to a pharmaceutical composition comprising a compound as defined above, and a pharmaceutically acceptable excipient.
[0017] In yet a further aspect, the invention provides methods for preparing the compounds defined above. Detailed Description of the Invention
[0018] The invention, in a broad sense, is based on the judicious recognition that compounds of Formula (RI) generally possess interesting RSV inhibitory activity.
[0019] The present invention will be further described with respect to particular embodiments and with reference to certain examples, but the invention is not limited thereto but only by the claims. Where the term "comprising" is used in the present description and claims it does not exclude other elements or steps. Where an indefinite or definite article is used when referring to a singular noun, eg "a" or "an", "the", this includes a plural of that noun unless otherwise specifically stated.
[0020] Whenever the term "substituted" is used in the present invention, it is intended, unless otherwise indicated, i.e. clear from context, indicating that one or more hydrogens, in particular from 1 to 4 hydrogens, preferably from 1 to 3 hydrogens, more preferably 1 hydrogen, on the atom or radical indicated in the expression using "substituted", are substituted by a selection from the indicated group, provided that the normal valency is not exceeded, and that the substitution gives give rise to a chemically stable compound, i.e., a compound sufficiently robust to survive isolation from a reaction mixture to a useful degree of purity, and formulation into a therapeutic agent.
[0021] As used herein, "C1-C6 alkyl" as a group or part of a group defines straight-chain or branched-chain saturated hydrocarbon radicals having 1 to 6 (1, 2, 3, 4, 5 or 6) carbon atoms. carbon such as methyl, ethyl, propyl, 1-methylethyl, butyl, pentyl, hexyl, 2-methylbutyl and the like.
[0022] "C1-C10 alkyl" as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having 1 to 10 carbon atoms such as the groups defined for C1-C6 alkyl and heptyl, octyl, nonyl , 2-methylhexyl, 2-methylheptyl, decyl, 2-methylnonyl, and the like.
[0023] "C1-C4 alkyloxy" or "C1-C4 alkoxy", as a group or part of a group, defines an O-C1-C4 alkyl radical, wherein C1-C4 alkyl independently has the meaning given above .
[0024] "C1-C6 alkyloxy" or "C1-C6 alkoxy", as a group or part of a group, defines an O-C1-C6 alkyl radical, wherein C1-C6 alkyl independently has the meaning given above .
[0025] The term "C3-C7 cycloalkyl", alone or in combination, refers to a cyclic saturated hydrocarbon radical having from 3 to 7 carbon atoms. Non-limiting examples of suitable C3-C7 cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
[0026] The term "-(CR8R9)m-" used herein defines m repeats of the CR8R9 subgroup, where each of these subgroups is independently defined.
[0027] The term "halo" or "halogen" as a group or part of a group is generic to fluorine, chlorine, bromine, iodine unless otherwise indicated, i.e. clear from the context.
[0028] A term of the form NRCOOR is identical to N(R)COOR.
[0029] Preferred examples of a 4 to 6 membered aliphatic ring optionally containing one or more heteroatoms selected from the group consisting of N, S and O are; cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, azetidinyl, thiolanyl, piperazinyl and pyrrolidinyl.
[0030] Heteroaryl represents a monocyclic 5- to 6-membered aromatic heterocycle containing one or more heteroatoms, each independently selected from the group consisting of O, S and N; or a bicyclic 8- to 12-membered aromatic heterocycle containing one or more heteroatoms each independently selected from the group consisting of O, S and N. Examples of such a heteroaryl are furanyl, thiophenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinoxalinyl , and benzimidazolyl.
[0031] It should be noted that the positions of the radicals in any molecular fraction used in the definitions can be anywhere in such a fraction as long as it is chemically stable.
[0032] Radicals used in variable definitions include all possible isomers unless otherwise indicated. For example, pentyl includes 1-pentyl, 2-pentyl and 3-pentyl.
[0033] When any variable occurs more than once in any constituent, each definition is independent.
[0034] Hereinafter, the term "compound of Formula (RI)" or "compounds of Formula (RI)" is intended to include their tautomers and stereoisomeric forms, and their pharmaceutically acceptable addition salts, and solvates.
[0035] The terms "stereoisomers", "stereoisomeric forms" or "stereochemically isomeric forms" hereinafter or hereinafter are used interchangeably.
[0036] The term "stereochemically isomeric forms" as used hereinbefore defines all possible compounds consisting of the same atoms bonded by the same sequence of bonds, but having different three-dimensional structures that are not interchangeable, which compounds of Formula (RI) may possess. .
[0037] It will be appreciated that some of the compounds of Formula (RI) may contain one or more centers of chirality and exist as stereochemically isomeric forms.
[0038] The invention includes all stereoisomers of the compound of Formula (RI) and its tautomers, either as a pure stereoisomer or as a mixture of two or more stereoisomers.
[0039] Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture. Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, that is, they are not related as mirror images. If a compound contains a double bond, the substituents may be in the E or Z configuration. Substituents on cyclic bivalent (partially) saturated radicals may have either the cis or trans configuration; for example, if a compound contains a disubstituted cycloalkyl group, the substituents may be in the cis or trans configuration. Therefore, the invention includes enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, whenever chemically possible.
[0040] Absolute setting is specified according to the Cahn-Ingold-Prelog system. The configuration on an asymmetric atom is specified by R or S. Resolved compounds whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
[0041] When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other isomers. Thus, when a compound of Formula (RI) is, for example, specified as (R), this means that the compound is substantially free of the (S) isomer; when a compound of Formula (RI) is, for example, specified as E, this means that the compound is substantially free of the Z-isomer; when a compound of Formula (RI) is, for example, specified as cis, this means that the compound is substantially free of the trans isomer.
[0042] Some of the compounds according to Formula (RI) may also exist in their tautomeric form. Such forms, while not explicitly indicated in the above formula, are intended to be included within the scope of the present invention.
[0043] Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms that said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of the present invention both in pure form and in admixture with each other are intended to be within the scope of the present invention.
[0044] Pure stereoisomeric forms of the compounds and intermediates of this invention can be obtained by applying procedures known in the art. The diastereomeric racemates of Formula (RI) can be obtained separately by conventional methods.
[0045] For some of the compounds of Formula (RI), their tautomers and stereoisomeric forms, and their pharmaceutically acceptable addition salts, and solvates; and the intermediates used in their preparation, the absolute stereochemical configuration has not been experimentally determined. A person skilled in the art is able to determine the absolute configuration of such compounds using methods known in the art such as, for example, X-ray diffraction.
[0046] The present invention is also intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Carbon isotopes include C-13 and C-14.
[0047] Accordingly, a compound according to the invention inherently comprises a compound with one or more isotopes of one or more elements, and mixtures thereof, including a radioactive compound, also called a radiolabeled compound, in which one or more atoms are not radioactive substances have been replaced by one of their radioactive isotopes. By the term "radiolabeled compound" is meant any compound according to Formula (RI) which contains at least one radioactive atom. For example, a compound can be labeled with radioactive isotopes that emit positrons or gamma radiation. For radioligand binding techniques, the 3H atom or the 125I atom is the atom of choice to be substituted. For imaging, the most commonly used radioactive isotopes that emit positrons (PET) are 11C, 18F, 15O, and 13N, all of which are produced in an accelerator and have half-lives of 20, 100, 2, and 10 minutes (min), respectively. . Since the half-lives of these radioactive isotopes are so short, it is only feasible to use them in institutions that have a local accelerator for their production, thus limiting their use. The most widely used of these are 18F, 99mTc, 201Tl and 123I. The manipulation of these radioactive isotopes, their production, isolation and incorporation into a molecule are known to the skilled person.
[0048] In particular, the radioactive atom is selected from the group of hydrogen, carbon, nitrogen, sulfur, oxygen and halogen. In particular, the radioactive isotope is selected from the group of 3H, 11C, 18F, 122I, 123I, 125I, 131I, 75Br, 76Br, 77Br and 82Br.
[0049] For therapeutic use, salts of compounds of Formula (RI) are those in which the counterion is pharmaceutically acceptable. However, salts of acids and bases which are not pharmaceutically acceptable can also be used, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether or not pharmaceutically acceptable, are included within the scope of the present invention.
[0050] The pharmaceutically acceptable acid and base addition salts as mentioned above are intended to comprise the therapeutically active non-toxic acid and base addition salt forms that the compounds of Formula (RI) are able to form. Pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such an appropriate acid. Suitable acids comprise, for example, inorganic acids such as hydrohalic acids, for example, hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric acids and the like; or organic acids such as, for example, acetic, propionic, hydroxyacetic, lactic, pyruvic, oxalic (i.e., ethanedioic), malonic, succinic (i.e., butanedioic acid), maleic, fumaric, malic (i.e., hydroxybutanedioic acid), tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, palmoic and the like.
[0051] Conversely, said salt forms may be converted by treatment with an appropriate base to the free base form.
[0052] Compounds of Formula (RI) containing an acidic proton can also be converted to their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. Suitable base salt forms include, for example, ammonium salts, alkali metal and alkaline earth salts, for example lithium, sodium, potassium, magnesium, calcium salts and the like, salts with bases organic compounds, for example, the salts of benzathine, N-methyl-D-glucamine, salts of hydrabamine, and salts with amino acids, such as, for example, arginine, lysine and the like.
[0053] The term solvate comprises the hydrates and solvent addition forms that the compounds of Formula (RI) are able to form, as well as their salts. Examples of such forms are, for example, hydrates, alcoholates and the like.
[0054] Without departing from the overall scope of the invention, certain embodiments are discussed in more detail below.
[0055] The terms described above and others used in the specification are well understood by practitioners.
[0056] Preferred features of the compounds of this invention are now shown.
[0057] The present invention relates to new compounds of Formula (RI),
or any stereoisomeric form thereof, wherein: Het is a heterocycle of any of the following formulas (a), (b), (c), (d):
each X is independently C or N; provided that at least two X's are C; each of R1a, R1b, R1c or R1d is independently selected from the group consisting of H, halogen, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 alkyloxy, N(R6)2, CO(R7), CH2NH2, CH2OH , CN, C(=NOH)NH2 , C(=NOCH3 )NH2 , C(=NH)NH2 , CF3 and OCF3; R1b or R1d is absent when the X to which it is attached is N; each R2 is -(CR8R9)m-R10; m is an integer from 0 to 6; each R3 is independently selected from the group consisting of H, halogen, aryl, heteroaryl, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 alkyloxy and CO(R7); each R6 is independently selected from the group consisting of H, C1-C6 alkyl, COOCH3 and CONHSO2CH3; each R7 is independently selected from the group consisting of H, C1-C6 alkyl, OH, C1-C6 alkyloxy, NH2, NHSO2N(C1-C6 alkyl)2, NHSO2NHCH3, NHSO2(C1-C6 alkyl), NHSO2(C3-C7 cycloalkyl) ) and N(C1-C6-alkyl)2 NR8R9 and NR9R10; each R8 and R9 is independently selected from the group consisting of H, C1-C10 alkyl and C3-C7 cycloalkyl; or R8 and R9 taken together form a 4- to 6-membered saturated ring optionally containing one or more heteroatoms selected from the group consisting of N, S and O; each R10 is independently selected from the group consisting of H, halogen, OH, CN, CF2H, CF3, C1-C6 alkyl, C3-C7 cycloalkyl, C(=O)C1-C6 alkyl, C(=O)C3-C7 cycloalkyl , C(=O)NR8R9, C(=O)OR8, 8 8 9 8 89 89 SO2R , C(=O)N(R )SO2R , C(=O)N(R )SO2N(RR ), NR R , 8 9 8 8 9 89 8 NR C(=O)OR , OC(=O)R , O-benzyl, NR SO2R , SO2NR R , SO2R , 8 9 8 12 8 8 9 11 OC(=O)NR R , OC(=O)NR R , N(R )C(=O)N(RR ), R , N(R8)C(=O)OR12, OR11, C(=O)R11 and a ring saturated with 4 the 6-membered one containing an oxygen atom; R11 is phenyl, pyridinyl or pyrazolyl; each of which may optionally be substituted by one or more substituents, each independently selected from the group consisting of CF3, CH3, OCH3, OCF3 and halogen; R12 is C1-C6 alkyl or C3-C7 cycloalkyl; each substituted by one or more substituents, each independently selected from the group consisting of CF3, CH3, OCH3, OCF3 and halogen; each Z is independently C or N, provided that at least two Z are C; Q and V independently each represent C=O, SO2, or pes independently represent an integer from 0 to 3, where the sum of pes must be at least 2, and when p = 0 or s = 0, then the carbon atom marked with * is directly linked to W; R20 and R21 are independently selected from the group consisting of hydrogen, hydroxyl, C1-C3 alkyl, C3-C7 cycloalkyl, CF3, OCH3, OCF3 and halogen; R22 is selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C3-C7 cycloalkyl, CF3, OCH3, OCF3 and halogen; R22 is attached to a Z other than N; W is selected from the group consisting of SO, SO2 , S, C, O and N, wherein such C or N is optionally substituted by one or more R23 ; R23 is selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6-R24 alkyl, SO2R24, SO2N(R24)2, aryl, heteroaryl, C(=O)OR24, OR24 , C(=O)R24, C(=O)N(R24 )2, OC(=O)N(R24 )2, P(=O)-(O-C1-C6-alkyl)2, N(R24 )2, NR25C(=O)OR24, NR25C(=O)N(R24)2, NR25SO2R24 and a 4 to 6 membered saturated ring containing an oxygen atom, wherein any such C1-C6 alkyl, C3 cycloalkyl -C7, aryl or heteroaryl is optionally substituted by one or more of the substituents selected from the group consisting of halogen, OH, CN, OCH3; R24 is selected from the group of hydrogen, OH, halogen, C1C6 alkyl, C3-C7 cycloalkyl, C(=O) C1-C6 alkyl, C(=O) C3-C7 cycloalkyl, aryl, heteroaryl, benzyl, and a saturated ring 4 to 6 membered containing an oxygen atom, wherein any of such C1C6 alkyl, C3-C7 cycloalkyl, C(=O) C1-C6 alkyl, C(=O) C3-C7 cycloalkyl, aryl, heteroaryl, benzyl is optionally substituted by one or more of the substituents selected from the group consisting of halogen, CF3 , OH, CN, OCH3 ,OC(=O)CH3 and C1-C3 alkyl substituted by at least one CN; R25 is selected from the group consisting of hydrogen and C1-C3 alkyl; aryl represents phenyl or naphthalenyl; heteroaryl represents a monocyclic 5- to 6-membered aromatic heterocycle containing one or more heteroatoms, each independently selected from the group consisting of O, S and N; or a bicyclic 8- to 12-membered aromatic heterocycle containing one or more heteroatoms, each independently selected from the group consisting of O, S and N; provided that Het does not satisfy a formula d(x)
or a pharmaceutically acceptable addition salt or solvate thereof.
[0058] In one embodiment, the present invention relates to compounds of formula (RI)
or any stereoisomeric form thereof, wherein Het is a heterocycle of any of the following formulas (a), (b), (c), (d):
each X is independently C or N; provided that at least two X's are C; each of R1a, R1b, R1c or R1d is independently selected from the group consisting of H, halogen, C1-C6 alkyl, C1-C6 alkyloxy, CF3 and OCF3; R1b or R1d is absent when the X to which it is attached is N; each R2 is -(CR8R9)m-R10; m is an integer from 2 to 6; each R3 is H, halogen or C1-C6 alkyl; each R8 and R9 is independently selected from the group consisting of H and C1-C10 alkyl; each R10 is independently selected from the group consisting of H, halogen, OH, CN, CF2H, CF3, C1-C6 alkyl, C3-C7 cycloalkyl, C(=O)NR8R9, C(=O)OR8, and SO2R8; each Z is independently C or N, provided that at least two Z are C; Q and V independently each represent CR21R21; pes independently represent an integer from 0 to 3, where the sum of pes must be minimally 2, and when p = 0 or s = 0, then the carbon atom marked with * is directly bonded to W; R20 and R21 are hydrogen; R22 is selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, CF3, OCH3, OCF3 and halogen; W is selected from the group consisting of SO 2 , S, C, O and N, wherein such C or N is optionally substituted by one or more R 23 ; R23 is selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6-R24 alkyl, SO2R24, SO2N(R24)2, aryl, heteroaryl, C(=O)OR24, OR24 , C(=O)R24, C(=O)N(R24 )2, OC(=O)N(R24 )2, P(=O)-(O-C1-C6-alkyl)2, N(R24 )2, NR25C(=O)OR24, NR25C(=O)N(R24)2, NR25SO2R24 and a 4 to 6 membered saturated ring containing an oxygen atom, wherein any such C1-C6 alkyl, C3 cycloalkyl -C7, aryl or heteroaryl is optionally substituted by one or more of the substituents selected from the group consisting of halogen, OH, CN, OCH3; R24 is selected from the group of hydrogen, OH, halogen, C1C6 alkyl, C3-C7 cycloalkyl, C(=O) C1-C6 alkyl, C(=O) C3-C7 cycloalkyl, aryl, heteroaryl, benzyl, and a saturated ring 4 to 6 membered containing an oxygen atom, wherein any of such C1C6 alkyl, C3-C7 cycloalkyl, C(=O) C1-C6 alkyl, C(=O) C3-C7 cycloalkyl, aryl, heteroaryl , benzyl is optionally substituted by one or more of the substituents selected from the group consisting of halogen, CF3, OH, CN, OCH3,OC(=O)CH3 and C1-C3 alkyl substituted by at least one CN; R25 is selected from the group consisting of hydrogen and C1-C3 alkyl; aryl represents phenyl or naphthalenyl; heteroaryl is furanyl, thiophenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinoxalinyl, or benzimidazolyl; or a pharmaceutically acceptable addition salt or solvate thereof.
[0059] Embodiments of compounds RI according to the present invention are represented by formulas Ia, Ib, Ic and Id, respectively.

[0060] In one embodiment, R1d is independently selected from the group consisting of H, halogen, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 alkyloxy, N(R6)2, CO(R7), CH2NH2, CH2OH, C (=NOH)NH2, C(=NOCH3)NH2, C(=NH)NH2, CF3 and OCF3;
[0061] Preferably, in any of the embodiments defined here, Het does not satisfy a formula d(x)
wherein R2 is as defined herein in either embodiment.
[0062] In an even more preferred embodiment, Het does not satisfy a formula d(y)
where R1d and R2 are as defined herein in either embodiment.
[0063] In another embodiment, Het is represented by the formula (a'), (b'), (c') or (d'):
wherein at least one X is N. More preferably, for Formulas (b') and (d'), only one X is N.
[0064] R1a, R1b, R1c or R1d are independently selected from the group consisting of H and halogen, more preferably from chlorine, bromine and fluorine. Most preferred is chlorine.
[0065] The compounds according to the present invention have an R2 radical which is -(CR8R9)m-R10 and where m is an integer from 0 to 6, 1 to 4 or 3 or 4.
[0066] Preferably, each R8 and R9 is independently chosen from H or C1-C6 alkyl. In a further embodiment, R2 is C1-C6-R10 alkyl. In a submodality, R2 is C3-C4-R10 alkyl.
[0067] Each R10 is independently selected from the group consisting of H, halogen, OH, CN, CF2H, CF3, C1-C6 alkyl, C3-C7 cycloalkyl, C(=O)C1-C6 alkyl, C(=O )C3-C7 cycloalkyl, C(=O)NR8R9, C(=O)OR8, SO2R8, C(=O)N(R8)SO2R9, C(=O)N(R8)SO2N(R8R9), NR8R9, NR8C (=O)OR9, OC(=O)R8, O-benzyl, NR8SO2R9, SO2NR8R9, SO2R8, OC(=O)NR8R9, OC(=O)NR8R12, N(R8)C(=O)N(R8R9) , R11, N(R8)C(=O)OR12, OR11, C(=O)R11 and a 4 to 6 membered saturated ring containing an oxygen atom.
[0068] In a specific embodiment, R10 is selected from the group consisting of C1-C3 alkyl, H, OH, CN, F, CF2H, CF3, SO2-C1-C3 alkyl, SO2C3-C6 cycloalkyl.
[0069] A particular embodiment of the invention relates to compounds having the Formula RII, RIII, RIV, RV, RVI or RVII;
or any stereoisomeric form thereof, wherein Het, X and R23 are defined as in any of the described embodiments.
[0070] In another embodiment of compounds of Formula RI, RII, RIII, RIV, RV or RVI, R23 is selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C1-C3-R24 alkyl, SO2R24, O -R24, phenyl, pyridinyl, pyrimidyl, pyrazolyl, C(=O)OR24, C(=O)R24, wherein any such C1-C6 alkyl, phenyl, pyridinyl, pyrimidyl, pyrazolyl is optionally substituted with a or more of the following substitutes; OCH3, halogen, OH and CN. General Synthetic Schemes
[0071] Compounds of formula RI, or pharmaceutically acceptable salts thereof, can be prepared according to the reaction schemes discussed below using synthetic methods known in the art of organic chemistry, or modifications and derivatizations that are familiar to those skilled in the art. technique. The starting materials used herein are commercially available or can be prepared by routine methods known in the art such as those methods described in standard reference books. Preferred methods include, but are not limited to, those described below.
[0072] During any of the following synthetic sequences, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules in question. This can be achieved by means of conventional protecting groups, such as those described in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference.
[0073] Unless otherwise indicated, the substituent in the schemes is defined as above. Isolation and purification of the products are accomplished by standard procedures, which are known to a chemist of ordinary skill.
[0074] The following schemes are exemplary of processes for manufacturing compounds of formula RI. In the schemes below, the numerals used, including numerals I through XXVIII, are used for convenience to designate formulas in the schemes.
[0075] Compounds of formula (Ia) can be synthesized, for example, using one of the methods shown in Scheme 1. In general, a fragment A or B is coupled with a fragment C resulting in derivatives of formula (Ia).
Scheme 1. General synthesis of compounds of formula (Ia)
[0076] For method 1, an example of suitable "coupling conditions" for reacting an A fragment with a C fragment to form compounds of formula (Ia) type is a Mitsunobu reaction. A suitable solvent for this type of reaction is THF (tetrahydrofuran).
[0077] Alternatively (but not limited to), a fragment-like compound B in which the LG is a leaving group, such as a halide, preferably chlorine, or sulfonate, can be reacted with a fragment-like compound C via a reaction base-mediated coupling. (Method 2) Possible bases for carrying out this reaction (but not limited to) are K2CO3, Cs2CO3, triethylamine, sodium hydride. A suitable (but not limited to) solvent for this type of base-mediated coupling is DMF (dimethylformamide) or THF (tetrahydrofuran).
[0078] Fragment A-like compounds can generally be prepared as illustrated in Scheme 2.
Scheme 2. General synthesis of A-fragment compounds
[0079] In general, fragment B compounds can be prepared from fragment A compounds through reaction with reagents such as (but not limited to) SOCl2, PBr3, p-TsCl, MsCl.
Scheme 3. General synthesis of B-fragment compounds
[0080] Fragment C-like intermediates of formula (VI) can be prepared as illustrated in Scheme 4.
Scheme 4. General synthesis of C-fragment compounds (VI)
[0081] Synthesis of spiro-2-oxo-indole derivatives and spiro-2-oxo-azaindole derivatives is shown in scheme 4. Intermediates of formula VI can be synthesized using the procedure illustrated in scheme 4. The substitution of ( U), which is a halide, preferably fluoride, or an alkyloxy group, preferably methoxy, of the nitropyridine or nitroaryl of formula I with tert-butyl ethyl malonate, in a suitable solvent such as THF or DMF, in the presence of a base such as sodium hydride or potassium carbonate, gives an intermediate of formula (II). Treatment of intermediate II with an acid such as trifluoroacetic acid or dry hydrochloric acid gives intermediate III. The latter can be converted to intermediate V by condensation with a bishalo compound IV, preferably bromine, in the presence of a suitable base such as potassium carbonate, sodium carbonate, sodium hydride and the like in a suitable solvent such as DMF, THF or a similar. Reduction of the nitro group of intermediate V when done in a stoichiometric manner using iron in the presence of ammonium chloride or tin chloride in the presence of concentrated hydrochloric acid directly gives compound VI. Alternatively, the intermediate of formula III may first be reduced catalytically using hydrogen in the presence of a catalyst such as palladium or platinum, in a suitable solvent such as methanol, to give intermediate VII. The latter can be transformed into intermediate VIII under acidic conditions using hydrochloric acid or the like in a suitable solvent such as alcohols, for example isopropanol. The condensation of intermediate VIII with a bishalo compound IV, preferably chlorine or bromine, is carried out in the presence of a suitable inorganic base such as potassium carbonate, sodium carbonate, sodium hydride or the like in a suitable solvent such as DMF, THF or the like or using an organic base such as sodium hexamethyldisilazide lithium alkyl bases, for example nBuLi in such a case as THF or ether to give intermediate VI.
Scheme 5. General synthesis of C-fragment compounds (VI)
[0082] Alternatively, compounds of formula VI may be prepared, but not limited to, by general procedures illustrated by Scheme 5.
[0083] Starting material IX may be commercially available or prepared using procedures known in the art. Acid X can be activated as the Weinreb amide using standard peptide coupling procedures, eg EDCI/HOBT, HATU, DCC, etc. Once the acid is activated as the Weinreb ester or amide, the aniline IX can be added to convert it to intermediate XI.
[0084] The reaction of intermediate XI with PG, where PG is a protecting group such as para-methoxybenzyl, benzyl, tert-butoxycarbonyl, mesyl or tosyl, in the presence of a suitable base such as potassium carbonate, cesium carbonate or sodium hydride in a suitable solvent such as DMF or THF gives intermediate XIII. Intermediate XIV was prepared according to the procedure reported in Lee, S. and J. F. Hartwig (2001). J. Org. Chem. 66(10): 3402-3415. Substitution of (U), which is a halo, preferably bromine, using Palladium (II) acetate as a catalyst in the presence of a base such as potassium tert-butoxide and a linker such as tricyclohexylphosphene in a solvent such as 1 ,4-dioxane, gives intermediate XIV. Removal of the protecting group in intermediate XIV can be accomplished using the conditions described in Green and Wurts, Protecting groups in Organic Synthesis 3rd Edition, to give intermediate VI.
[0085] Scheme 6 illustrates a method for preparing compounds of formula Ib, where R1b, R2, R22, Q, V, W, X and Z are defined as above.
[0086] Referring to Scheme 6, a compound of formula Ib can be synthesized by coupling 2-hydroxymethylene XV-a imidazopyridines with spiro-oxo-indole or spiro-oxo-azaindole VI in a method known in the art such as as a Mitsunobu reaction using for example triphenylphosphine azadiisopropyl dicarboxylate in a suitable solvent such as DMF or THF. Alternatively, a compound of formula Ib can be prepared by substituting (LG) where (LG) is a leaving group, which is a halide, preferably chloride XV-b, or a sulfonate such as mesylate XV-c in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF. Scheme 6
Preparation of compounds XV-b and XV-c
[0087] Treatment of the XV-a alcohol with thionyl chloride provides 2-chloromethyl imidazopyridines XV-b. Alternatively, the alcohol XV-a can be transformed to intermediate XV-c by a reaction with methanesulfonyl chloride in the presence of an organic base such as triethylamine or diisopropylethylamine in a suitable solvent such as dichloromethane (scheme 7). Scheme 7
Preparation of compound XV-a
[0088] Compounds of formula XV-a are commercially available or can be prepared, but not limited to, by general procedures illustrated by Scheme 8, wherein R1b, R2, X are defined as above. Referring to Scheme 8 below, haloheteroaryls XVI, where (U) is a halide, preferably fluoride, may be treated with primary amines of formula XVII in the presence of a suitable base such as potassium carbonate and the like. , in a suitable solvent such as ethanol or dichloromethane at a reaction temperature ranging from room temperature to 100°C to give compounds of formula XVIII. Hydrogenation of the nitro group using well preceded conditions such as Pd/C, or other catalyst, under hydrogen or Fe/EtOH/CaCl 2 can yield diamine of formula XIX. Alternatively, hydrogenation of the nitro group of compound XX using well preceded conditions such as Pd/C, or other catalyst, under an atmosphere of hydrogen or Fe/EtOH/CaCl2 yields diamine of formula XXI. This can be treated with the aldehydes of formula XXII in the presence of a suitable reducing agent such as NaBH(OAc)3, or Na(CN)BH3 in solvents such as methylene chloride, DMF or THF, at about room temperature. to give compounds of formula XIX. The imidazole ring can be formed by treating diamines XIX with glycolic acid or an ester like XXV under strong acidic conditions, such as aqueous hydrochloric acid, at elevated temperature such as reflux to give the alcohols of formula XV-a.
[0089] Alternatively, diamines XIX can be condensed with dialkoxyacetate of formula XXIV, in the presence of acetic acid, in a suitable solvent such as methanol to give the acetal XV-e. The acetal of compounds XV-e can be removed with acids such as hydrochloric acid to give the aldehydes of formula XV-f. The resulting aldehydes of formula XV-f can be reduced to alcohols using a suitable reducing agent such as NaBH4 or LiAlH4 in a suitable solvent such as ethanol or THF to give the desired alcohols of formula XV-a. Additionally, diamines XIX can be cyclized with dialkyl oxalate of formula XXIII in a suitable solvent such as ethanol at elevated temperature with or without microwave heating to produce imidazoles of formula XV-d. Alternatively, compounds of formula XV-d can be prepared in a two-step synthesis starting from diamines XIX. First, diamine XIX can be reacted with an alkyl trihaloacetimidate, preferably methyl 2,2,2-trichloroacetimidate, in an acidic medium, preferably acetic acid, at a temperature ranging between 25 and 50°C to give a compound of formula XV -g. Second, a reaction of compounds of formula XV-g with metalcarbonate, preferably sodium carbonate in a suitable solvent such as methanol, leads to compounds of formula XV-d. Compounds XV-d may subsequently be reduced to the desired alcohols of formula XV-a using a suitable reducing agent such as NaBH4 or LiAlH4 in a suitable solvent such as ethanol or THF. Scheme 8

[0090] An alternative route for preparing compounds of type XV-a is illustrated in Scheme 9. Diamine XIX can first be coupled to an alkyl glycolic acid or an ester such as XXV under strong acidic conditions such as aqueous hydrochloric acid. , at elevated temperature such as reflux to give the alcohols of formula XXVI. This alcohol may be protected by a PG, where PG is a protecting group such as, but not limited to, a trityl which consequently results in compounds XXVII. A suitable solvent for this type of reaction may be, but not limited to, dichloromethane. The treatment of compound XXVII with compound XXVIII, wherein LG is a leaving group, such as halide, preferably bromide, or sulfonate, in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF, gives compound XV-h. Removal of PG in compound XV-h can be done in the presence of an acid such as hydrochloric acid in the presence of a solvent, not limited to, such as dioxane to give compound XV-a. Scheme 9

[0091] Compounds of formula Ic, or pharmaceutically acceptable salts thereof, can be prepared according to the reaction schemes discussed below. Unless otherwise indicated, substituents in the schemes are defined as above. Isolation and purification of the products are accomplished by standard procedures, which are known to a chemist of ordinary skill.
[0092] Referring to Scheme 10, a compound of formula Ic, where R1c, R2, R3, R22, Q, V, W and Z are defined as above, can be synthesized by indole coupling of 2-hydroxymethylene ( XV-i) with (VI) with a method known in the art such as a Mitsunobu reaction using azadiisopropyl dicarboxylate and triphenylphosphine in a suitable solvent such as DMF or THF. Alternatively, a compound of formula Ic can be prepared by replacing LG (leaving group), which is a halide, preferably chloride (XV-j), or a sulfonate such as mesylate (XV-k) in the presence of a base such as hydride. sodium, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF. Scheme 10
Preparation of compound XV-i
[0093] The XXIX starting materials used in this invention are commercially available, or can be synthesized, but not limited to, by methods known in the art such as Reissert synthesis or Fischer synthesis, the reaction of such indoles with R2-LG , where LG is a leaving group such as halide, preferably bromide, or sulfonate, in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF, gives the compound XXX ( scheme 11). Conversion of the alkyl ester of compound XXX to the alcohol XV-i can be carried out with metal hydride such as lithium aluminum hydride or sodium borohydride in a suitable solvent such as THF, methanol or ethanol. Scheme 11

[0094] Treatment of the alcohol XV-i with thionyl chloride provides 2-chloromethyl indole XV-j. Alternatively, the alcohol XV-i can be transformed to intermediate XV-k by a reaction with methanesulfonyl chloride in the presence of an organic base such as triethylamine or diisopropylethylamine in a suitable solvent such as dichloromethane (scheme 12). Scheme 12

[0095] Scheme 13 illustrates a method for preparing compounds of formula (Id), where R1d, R2, R3, R22, Q, V, W, X and Z are defined as above.
Scheme 13: General synthesis of compounds of formula (Id)
[0096] A compound of formula Id can be synthesized by coupling azaindole to 2-hydroxymethylene XV-I as a spiro-oxo-indole or spiro-oxo-azaindole VI in a method known in the art such as the Mitsunobu reaction using dicarboxylate of azadiisopropyl (DIAD) and triphenylphosphine in a suitable solvent such as DMF or THF. Alternatively, compounds of formula Id can be prepared by substitution of LG, where LG is a leaving group, which is a halide, preferably chloride XV-m or sulfonate such as mesylate XV-n in the presence of a base such as, but not limited to, sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF.
Scheme 14: General synthesis of type XV-l compounds
[0097] Compound XV-1 is prepared according to the methods as illustrated in Scheme 14.
[0098] The XXXI starting materials used in this invention, according to method 1, are commercially available, or can be synthesized, but not limited to, by methods known in the art such as Reissert synthesis or Fischer synthesis. The reaction of such a compound with R2-LG, where LG is a leaving group such as halide, preferably bromide, or sulfonate, in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a solvent suitable such as DMF or THF, gives compound XXXII. Conversion of the alkyl ester of compound XXXII to the alcohol XV-I can be done with a metal hydride such as lithium aluminum hydride or sodium borohydride in a suitable solvent such as THF or methanol.
[0099] Alternatively, a type XV-l compound can also be synthesized as shown in scheme 14, method 2. The commercially available XXXIII starting material is protected by a PG, where PG is a protecting group such as, but not limited to a, a tosyl which consequently results in compound XXXIV. A suitable solvent for this type of reaction may be, but not limited to, toluene. Metallation of compound XXXIV followed by treatment with compound XXXV, where the halide is preferably chloride, in a suitable solvent such as, but not limited to, THF, yields compound XXXVI. Removal of the PG in compound XXXVI can be done in the presence of a base such as potassium carbonate or cesium carbonate in a suitable solvent such as THF and methanol to obtain indole XXXVII. The reaction of indoles XXXVII with R2-LG, where LG is a leaving group such as a halide, preferably bromide, or sulfonate, in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as as DMF or THF, gives compound XXXVIII. Conversion of the alkyl ester of compound XXXVIII to the alcohol XV-I can be carried out with a metal hydride such as lithium aluminum hydride or sodium borohydride in a suitable solvent such as THF or ethanol.
Scheme 15: General synthesis of type XV-m and XV-n compounds
[00100] Treatment of the XV-1 alcohol with reagents such as, but not limited to, SOCl2, PBr3, p-TsCl, MsCl provides 2-chloromethyl indole XV-m or XV-n type compounds.
[00101] Compounds of Formula (RI) can be converted to the corresponding N-oxide forms following procedures known in the art to convert a trivalent nitrogen to its N-oxide form. Said N-oxidation reaction can generally be carried out by reacting the starting material of Formula (RI) with appropriate organic or inorganic peroxide. Suitable inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or alkaline earth metal peroxides, for example sodium peroxide, potassium peroxide; suitable organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo-substituted benzenecarboperoxoic acid, for example 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids, for example peroxoacetic acid, alkyl hydroperoxides, for example, t-butyl hydroperoxide. Suitable solvents are, for example, water, short-chain alcohols, for example, ethanol and the like, hydrocarbons, for example, toluene, ketones, for example, 2-butanone, halogenated hydrocarbons, for example, dichloromethane, and mixtures of such solvents. .
[00102] All starting materials are commercially available or can be prepared by those skilled in the art.
[00103] Stereochemically pure forms of compounds of Formula (RI) can be obtained by applying procedures known in the art. Diastereomers can be separated by physical methods such as selective crystallization and chromatography techniques, eg countercurrent distribution, liquid chromatography and the like. Suitable physical separation methods which may advantageously be employed are, for example, selective crystallization and chromatography, for example column chromatography.
[00104] The compounds of Formula (RI) as prepared in the processes described above are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. Racemic compounds of Formula (RI) which are sufficiently basic or acidic can be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are released therefrom by alkali or acid. An alternative way of separating the enantiomeric forms of the compounds of Formula (RI) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction takes place stereospecifically. Preferably, if a specific stereoisomer is desired, that compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
[00105] In a further aspect, the present invention pertains to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (RI) as specified herein, or a compound of any one of the embodiments of compounds of Formula (RI) ) as specified herein, and a pharmaceutically acceptable carrier. A therapeutically effective amount in this context is an amount sufficient to act prophylactically against, to stabilize or to reduce viral infection, and in particular RSV viral infection, in infected individuals or individuals being at risk of being infected. In a still further aspect, this invention relates to a process for preparing a pharmaceutical composition as specified herein, which comprises intimately mixing a pharmaceutically acceptable carrier with a therapeutically effective amount of a compound of Formula (RI), as specified herein, or of a compound of any one of the embodiments of compounds of Formula (RI) as specified herein.
[00106] Therefore, the compounds of the present invention or any embodiment thereof may be formulated into various dosage forms for purposes of administration. As suitable compositions, all compositions usually employed for systemic drug administration can be cited.
[00107] To prepare the pharmaceutical compositions of the present invention, an effective amount of the particular compound, optionally in the form of an addition salt, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier can take a wide variety of forms. in ways depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly for administration orally, rectally, percutaneously, or by parenteral injection. Oral administration is preferred. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, although other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution can be prepared. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations intended to be converted, shortly before use, to liquid form preparations. In compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
[00108] The compounds of the present invention may also be administered via inhalation or oral insufflation by means of methods and formulations employed in the art for administration via this route. Thus, in general the compounds of the present invention can be administered to the lungs in the form of a solution, a suspension or a dry powder, with a solution being preferred. Any system developed for the delivery of solutions, suspensions or dry powders via inhalation or oral insufflation is suitable for the administration of the present compounds.
[00109] Thus, the present invention also provides a pharmaceutical composition adapted for administration or insufflation through the mouth comprising a compound of Formula (RI) and a pharmaceutically acceptable carrier. Preferably, the compounds of the present invention are administered by inhalation of a solution in nebulized or aerosolized doses.
[00110] It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.
[00111] The compounds of Formula (RI) show anti-viral properties. Viral infections treatable using the compounds and methods of the present invention include those infections caused by ortho- and paramyxoviruses and in particular by human and bovine respiratory syncytial virus (RSV). A number of the compounds of this invention are in addition active against mutated strains of RSV. Additionally, many of the compounds of this invention show a favorable pharmacokinetic profile and have attractive properties in terms of bioavailability, including an acceptable half-life, AUC and peak values and not having unfavorable phenomena such as insufficient rapid onset and tissue retention.
[00112] The in vitro antiviral activity against RSV of the present compounds was tested in a test as described in the experimental part of the description, and can also be demonstrated in a virus yield reduction assay. The in vivo antiviral activity against RSV of the present compounds can be demonstrated in a test model using cotton rats as described in Wyde et al. (Antiviral Research (1998), 38, 31-42).
[00113] Because of their antiviral properties, particularly their anti-RSV properties, the compounds of Formula (RI) or any modality thereof, their tautomers and stereoisomeric forms, and their pharmaceutically acceptable addition salts, and solvates are useful. in the treatment of individuals experiencing a viral infection, particularly an RSV infection, and for the prophylaxis of these infections. In general, the compounds of the present invention may be useful in the treatment of warm-blooded animals infected with viruses, in particular respiratory syncytial virus.
[00114] The compounds of the present invention or any embodiment thereof can therefore be used as medicaments. Said use as a medicament or method of treatment comprises systemic administration to virally infected subjects or to subjects susceptible to viral infections of an amount effective to combat conditions associated with viral infection, in particular RSV infection.
[00115] The present invention also relates to the use of the present compounds or any modality thereof in the manufacture of a medicament for the treatment or prevention of viral infections, particularly RSV infection.
[00116] The present invention further relates to a method of treating a warm-blooded animal infected with a virus, or being at risk of infection with a virus, in particular RSV, said method comprising administering a antivirally effective amount of a compound of Formula (RI), as specified herein, or a compound of any one of the embodiments of compounds of Formula (RI), as specified herein.
[00117] The exact dosage and frequency of administration depend on the particular compound of Formula (RI) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of the disorder, and the patient's general physical condition. particular as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the judgment of the physician prescribing the compounds of the present invention. The effective daily amount ranges mentioned above in that document are, therefore, for guidance only.
[00118] Likewise, the combination of another antiviral agent and a compound of Formula (RI) can be used as a medicine. Thus, the present invention also relates to a product containing (a) a compound of Formula (RI), and (b) another antiviral compound, as a combined preparation for simultaneous, separate or sequential use in antiviral treatment. The different drugs can be combined in a single preparation together with pharmaceutically acceptable carriers. For example, compounds of the present invention can be combined with interferonbet or tumor necrosis factor-alpha in order to treat or prevent RSV infections.
[00119] The invention will hereinafter be illustrated with reference to the following non-limiting examples. Experimental part Synthesis of intermediates Intermediate 1b: Synthesis of 2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one Method 1
n-BuLi (108 mL, 216 mmol, 2M in THF) was added to a solution of oxindole 1a (CAS number: 59-48-3, 11 g, 82.6 mmol) at -78°C in THF (1000 mL). After complete addition, TMEDA (25 g, 214.76 mmol) was added, keeping the internal temperature < -70°C. After one hour at -78°C, bis(2-bromomethyl)ether (CAS number: 5414-19-7, 57.5 g, 247.8 mmol) was added and the reaction warmed to room temperature. After 48 h, the reaction was quenched with H2O and the mixture was partitioned between EtOAc and H2O. The aqueous solution was extracted with EtOAc and the combined organic layers were washed with brine, dried over MgSO 2 , filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography, eluting with a gradient of CH2Cl2:MeOH = 100:0 to 97:3 to give 8% 2',3',5',6'-tetrahydrospiro[indoline- 3,4'-pyran]-2-one 1b. method 2

[00120] Oxindole 1a (CAS number: 59-48-3, 40 g, 264.659 mmol) was added to a solution of LiHMDS (800 mL, 800 mmol) at -78°C. The mixture was stirred one hour at -78°C. Bis(2-bromomethyl)ether (CAS number: 5414-19-7, 61.378 g, 264.659 mmol) was then added, keeping the internal temperature < -50°C. The reaction was warmed to room temperature. After 18 hours, the reaction was quenched with H2O and the mixture was partitioned between EtOAc and H2O. The aqueous solution was extracted with EtOAc and the combined organic layers were washed with brine, dried over MgSO 2 , filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography, eluting with a gradient of petroleum ether:ethyl acetate = 3:1 to give 10.187 g (17%) of 2',3',5',6'- tetrahydrospiro[indoline-3,4'-pyran]-2-one 1b. Intermediate 2c: Synthesis of tert-butyl 2-oxospiro[indoline-3,4'-piperidine]-1'-carboxylate
Step 1
[00121] 1'-Benzylspiro[indoline-3,4'-piperidin]-2-one 2a was synthesized in 59% yield (52 g) following method 2 used for the synthesis of 2',3',5 ',6'-Tetrahydrospiro[indoline-3,4'-pyran]-2-one 1b, using N,N-bis(2-chloroethyl)benzenemethanamine (CAS number: 55-51-6, 70 g, 302 mmoles) instead of bis(2-bromomethyl)ether. step 2
[00122] A solution of 1'-benzylspiro[indoline-3,4'-piperidin]-2-one 2a (5 g, 17.10 mmol, 1 eq.) in methanol (100 mL) was hydrogenated at RT with Pd 10% /C (0.18 g) as a catalyst for 15 hours. The catalyst was filtered and the solvent was evaporated under vacuum. The residue was then recrystallized from DIPE/acetonitrile to give 2.7 g (78% yield) of spiro[indoline-3,4'-piperidin]-2-one 2b. step 3
[00123] To a solution of spiro[indoline-3,4'-piperidin]-2-one 2b (2.73 g, 11.42 mmol, 1 eq.) in THF (100 mL) was added Boc2O (2, 74 g, 12.57 mmol) and triethylamine (2.38 mL, 17.135 mmol) at RT. The mixture was stirred at room temperature for 4 h. The solvent was then evaporated in vacuo and the residue treated with a mixture of water and DCM. The aqueous layer was extracted with DCM (3x) and the organic layers were combined, dried over Na2SO4, filtered and concentrated to give tert-butyl-2-oxospiro[indoline-3,4'-piperidine]-1'-carboxylate 2c ( 4.02 g, quantitative yield) as a white foam. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.44 (s, 9H) 1.56 - 1.73 (m, 4H) 3.55 - 3.79 (m, 4H) 6.86 (dd, J=7.70, 0.40 Hz, 1H) 6.95 (td, J=7.59, 1.10 Hz, 1H) 7.19 (td, J=7.70, 1 .10 Hz, 1H) 7.43 (dd, J=6.80, 0.70 Hz, 1H) 10.41 (sl, 1H); m/z = 303.05 (M+H)+. Intermediate 3f: Synthesis of tert-butyl 2'-oxospiro[azetidine-3,3'-indoline]-1-carboxylate
Step 1
[00124] To a stirred solution of 2-bromoaniline (150 g, 872 mmol, 1 eq.) and DMAP (138.5 g, 1133 mmol, 1.3 eq.) in CH2Cl2 (2500 mL) was added N- (tert-butoxycarbonyl)azetidine-3-carboxylic acid (CAS number: 142253-55-2, 176 g, 872 mmol, 1 eq) in one portion followed by the addition of EDCI (217 g, 1133 mmol, 1.3 eq.) in one portion at room temperature. The resulting mixture was stirred at room temperature overnight. It was then washed successively with 10% aqueous citric acid solution, water, saturated aqueous Na2CO3 solution, and brine, and dried over Na2SO4. After filtration, the solvent was removed in vacuo to give tert-butyl 3-((2-bromophenyl)carbamoyl)azetidine-1-carboxylate 3b (328 g, 85% yield). step 2
[00125] A mixture of tert-butyl 3-((2-bromophenyl)carbamoyl)azetidine-1-carboxylate 3b (307 g, 864 mmol, 1 eq.), 4-methoxybenzyl chloride (203 g, 1296 mmol, 1.5 eq.) and K2CO3 (358 g, 2593 mmol, 3 eq.) in CH3CN (3000 mL) was refluxed overnight. The solution was then filtered, and the solid was washed with CH3CN (1000 mL). The filtrate was concentrated in vacuo and the crude product was triturated in petroleum ether/ethyl acetate (30:1) to give tert. - butyl 3c (380 g, 90% yield). step 3
[00126] Pd(OAc)2 (2.25 g, 10 mmol, 0.025 eq.) and PCy3 (2.8 g, 10 mmol, 0.025 eq.) were added to the solution of 3-((2-bromophenyl)( tert-Butyl 4-methoxybenzyl)carbamoyl)azetidine-1-carboxylate 3c (190 g, 400 mmol, 1 eq.) and t-BuONa (57.6 g, 600 mmol, 1.5 eq.) in dioxane (960 mL) under N2 atmosphere. The reaction was stirred at 90°C overnight under a N 2 atmosphere. The solution was then filtered and concentrated in vacuo. The residue was dissolved in CH2Cl2, washed with NH4Cl, brine and dried over Na2SO4. The solvent was removed in vacuo to give 158 g (quantitative yield) of tert-butyl 1'-(4-methoxybenzyl)-2'-oxospiro[azetidine-3,3'-indoline]-1-carboxylate 3d. step 4
[00127] CF3SO3H (119 mL, 1350 mmol, 3 eq.) was added to a mixture of tert. -butyl 3d (178 g, 450 mmol, 1 eq. crude) in TFA (750 mL). The mixture was stirred overnight at 25°C. The solvent was then removed under vacuum and the residue (78.4 g) was used directly in the next step. step 5
[00128] A solution of spiro[azetidine-3,3'-indolin]-2'-one 3e (78.4 g, 450 mmol, 1 eq. crude) in CH2Cl2 (1500 mL) was poured into a mixture of K2CO3 (186.6 g, 1350 mmol, 3 eq.) in ice water (1500 mL). The aqueous layer was separated and washed with CH2Cl2 (3*500 mL). The aqueous layer was diluted in THF (1500 mL) and (Boc) 2 O (98.2 g, 450 mmol, 1 eq.) was added. The solution was stirred overnight. 500 ml of a solution of ammonium in MeOH (7M) was then added dropwise to the above solution. The organic solvent was evaporated under vacuum. The aqueous solution was extracted with CH2Cl2 (800 mL*3), washed with brine, dried over Na2SO4, filtered and then concentrated in vacuo. The resulting residue was washed with methyl t-butyl ether to give the pure product tert-butyl 2'-oxospiro[azetidine-3,3'-indoline]-1-carboxylate 3f (44 g, 37% yield) . Intermediates 4c and 4d: Synthesis of (3S) and (3R)-hydroxyspiro[cyclobutane-1,3'-indolin]-2'-one
Step 1
[00129] In a flask equipped with a condenser, a mixture consisting of benzyl bromide (62.43 g, 365.03 mmol, 1 eq.), 2-(bromomethyl)oxirane (50 g, 365.03 mmol, 1 eq.) and HgCl 2 (100 mg) was heated with stirring at 155°C for 16 hours. The product was isolated by vacuum disposal through a 30 cm Vigreux condenser (110-115, 0.5 mm Hg) to provide a colorless liquid. The residue was purified by column chromatography over silica gel (eluent: dichloromethane) to give 65 g of (((1,3-dibromopropan-2-yl)oxy)methyl)benzene 4a. step 2
[00130] Oxindole 1a (20 g, 150.210 mmol, 1 eq.) was dissolved in THF (400 mL) and HMPA (40 mL). The reaction mixture was cooled to -78°C, then n-BuLi (132.185 mL, 330.462 mmol, 2.2 eq.) was added. The reaction mixture was stirred at -78°C for one hour. Then (((1,3-dibromopropan-2-yl)oxy)methyl)benzene 4a (46.27 g, 150.210 mmol, 1 eq.) was added. The mixture was successively stirred at room temperature for 14 hours, quenched with water and extracted with dichloromethane. The residue was purified by column chromatography over silica gel (eluent: petroleum ether: ethyl acetate 10:1). The product fractions were collected and the solvent was evaporated to give 15 g of the desired product 3-(benzyloxy)spiro[cyclobutane-1,3'-indolin]-2'-one 4b. step 3
[00131] A mixture of 3-(benzyloxy)spiro[cyclobutane-1,3'-indolin]-2'-one 4b (15 g, 53.699 mmol, 1 eq) and Pd/C (1.5 g) in methanol (150 mL) was hydrogenated under 30 psi pressure for 15 hours. The reaction mixture was filtered through a pad of celite which was washed several times with CH3OH. The combined filtrates were evaporated to dryness. The residue was purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 3: 1) to provide the racemic mixture of (3)-hydroxyspiro[cyclobutane-1,3'-indolin]-2 '-one, whose 4c and 4d enantiomers were separated by high performance liquid chromatography (HPLC Condition: Column: SYNERGI 250*50 10 µm, Flow rate: 80 mL/min, Mobile Phase A: Purified water (containing TFA at 0.075%), Mobile Phase B: Acetonitrile, Gradient: 5-30% (%B)). The desired fractions were collected, evaporated to remove CH3CN in vacuo and made alkaline with a saturated solution of NaHCO3. The aqueous solution was extracted with CH2Cl2. The organic layers were dried, filtered and the solvent evaporated to give 4.59 g of (3S)-hydroxyspiro[cyclobutane-1,3'-indolin]-2'-one 4c and 0.89 g of (3R)- hydroxyspiro[cyclobutane-1,3'-indolin]-2'-one 4d. Intermediate 5c: Synthesis of tert-butyl 5-fluoro-2-oxospiro[indoline-3,4'-piperidine]-1'-carboxylate

[00132] 5-Fluoroindolin-2-one 5a (35 g, 231.576 mmol, 1 eq.) was added to a solution of LiHMDS (700 mL, 700 mmol, 3 eq) at -78°C. The mixture was stirred one hour at -78°C, then tert-butyl bis(2-chloroethyl)carbamate 5b (56.075 g, 231.576 mmol, 1 eq) was added, keeping the internal temperature < -50°C. The reaction was then warmed to room temperature for two hours, and the reaction was refluxed overnight. The mixture was quenched with H2O and the mixture was partitioned between EtOAc and H2O. The aqueous solution was extracted with EtOAc and the combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The resulting residue was purified by high performance liquid chromatography (HPLC Condition: Column: Synergi-10 μm, 250x50 mm ID, Flow rate: 80 mL/min, Mobile Phase A: Purified water (containing 0.1% TFA). Mobile Phase B: Acetonitrile, Gradient: 35-65% (%B)) to give 5.003 g (7% yield) of 5-fluoro-2-oxospiro[indoline-3,4'-piperidine]-1'-carboxylate of tert-butyl 5c. Intermediate 6a: Synthesis of 5-fluoro-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one

[00133] 5-Fluoroindolin-2-one 5a (30 g, 198.49 mmol, 1.0 eq.) was added to LiHMDS (1M in THF, 595.48 mL, 595.48 mmol, 3.0 eq.) at -78°C. The mixture was stirred at -78°C for 10 minutes and warmed to 0°C. The mixture was stirred at 0°C for 30 minutes, then bis(2-bromomethyl)ether (CAS number: 5414-19-7, 46.03 g, 198.49 mmol, 1.0 eq.) was added. The mixture was stirred at room temperature overnight. Water (300 mL) was added to the reaction mixture. The resulting precipitate was filtered and washed with water to give 5-fluoro-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one 6a (12 g, yield of 13%). Intermediate 7b: Synthesis of 4-fluoro-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one

[00134] 4-Fluoroindolin-2-one 7a (9.5 g, 62.856 mmol, 1.0 eq.) was added to LiHMDS (1 M in THF, 188.568 mL, 188.568 mmol, 3.0 eq.) at -78°C. The mixture was stirred at -78°C for 10 minutes and warmed to 0°C. The mixture was stirred at 0°C for 30 minutes, then bis(2-bromomethyl)ether (14.577 g, 62.856 mmol, 1.0 eq.) was added. The mixture was stirred at room temperature overnight. Water (300 mL) was added to the reaction mixture. The resulting solid was filtered and washed with water to give 4-fluoro-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one 7b (1.61 g , 12% yield. Intermediate 8d: Synthesis of Spiro[cyclopentane-1,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one
Step 1
[00135] To a solution of tert-butyl ethyl malonate (160 g, 850 mmol) in THF (1600 mL) was added NaH (80 g, 2118 mmol) portionwise at 0°C. The mixture was stirred for one hour at 15°C, then 4-chloro-3-nitropyridine (112 g, 706 mmol) was added portionwise at 0°C. The mixture was stirred for one hour at 15°C. The reaction was quenched with water and 1N HCl was added until pH = 5. The mixture was extracted with ethyl acetate twice. The organic layers were washed with brine, dried and evaporated in vacuo to give 1-(tert-butyl) 3-ethyl 2-(3-nitropyridin-4-yl)malonate 8a (250g), which was used without purification. additional in the next step. step 2
[00136] To a solution of 1-(tert-butyl) 3-ethyl 2-(3-nitropyridin-4-yl)malonate 8a (crude, 250 g, 706 mmol) in CH2Cl2 (1500 mL) was added TFA (250 ml). After 14 h of stirring at 60°C, the mixture was evaporated. A 10% aqueous solution of NaHCO3 was then added and the mixture was extracted with ethyl acetate twice. The organic layers were washed with brine, dried and evaporated in vacuo to give ethyl 2-(3-nitropyridin-4-yl)acetate 8b (180g), which was used without further purification in the next step. step 3
[00137] Ethyl 2-(3-Nitropyridin-4-yl)acetate 8b (50g, 238mmols), 1,4-dibromobutation (50g, 238mmols), K2CO3 (100g, 714mmols) and sieve molecular 4A (50 g) in DMF (500 ml) were stirred for 14 hours at 80°C. 1N HCl was then added and the mixture was extracted with CH2Cl2 twice. The organic layers were washed with 10% aqueous NaHCO3 solution (2x), brine (2x), dried and evaporated in vacuo. The residue was purified by silica gel column chromatography (eluent: CH2Cl2/ethyl acetate = 10/1) to give 8.4 g (15% yield in total for the three steps) of 1-(3 ethyl-nitropyridin-4-yl)cyclopentane-1-carboxylate 8c. step 4
[00138] Ethyl 1-(3-Nitropyridin-4-yl)cyclopentane-1-carboxylate 8c (8.4 g, 31.8 mmol), Fe (7 g, 127 mmol) and NH4Cl (7 g, 127 mmols) in CH3OH (80 mL), THF (80 mL) and H2O (80 mL) were stirred and refluxed for 3 h. The mixture was then filtered and the solvent was evaporated under vacuum. A 10% aqueous solution of NaHCO3 was added and the mixture was extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried and evaporated in vacuo. The residue was washed with CH3CN (2x) and the solid was collected and dried to give 4 g (67% yield) of spiro[cyclopentane-1,3'-pyrrolo[2,3-c]pyridin]-2 '(1'H)-one 8d. Intermediate 9c: Synthesis of 2,3,5,6-tetrahydrospiro[yran-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one
Step 1: synthesis of ethyl 2-(3-aminopyridin-4-yl)acetate (intermediate 9a)
[00139] A mixture of ethyl 2-(3-nitropyridin-4-yl)acetate 8b (65 g, 309 mmol, 90% purity, 1 eq.) in methanol (1500 mL) was hydrogenated at 20° C (atmospheric pressure) with 10% Pd/C (6.5 g) as a catalyst for 16 hours. After uptake of H 2 (3 equiv), the catalyst was filtered and the filtrate was evaporated in vacuo to give 50 g (Yield: 90%) of ethyl 2-(3-aminopyridin-4-yl)acetate 9a, which was used without further purification in the next step. Step 2: synthesis of 1,3-dihydro-2H-pyrrolo[2,3-c]pyridin-2-one (intermediate 9b)
[00140] Ethyl 2-(3-aminopyridin-4-yl)acetate 9a (34 g, 189 mmol, 1 eq.) was dissolved in 1.4N HCl (1000 mL) and diisopropyl ether ( 1000 ml). The mixture was stirred at room temperature overnight. The separated organic layer was separated and washed with H2O. The combined aqueous layers were washed with CH2Cl2 and evaporated to near dryness. The resulting precipitate was filtered and dried (vacuum, 60°C, two hours) to give 26 g (Yield: 94%) of 1,3-dihydro-2H-pyrrolo[2,3-c]pyridin-2 -one 9b as a salt of hydrochloric acid. Step 3: Synthesis of 2,3,5,6-tetrahydrospiro[yran-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one (intermediate 9c)
[00141] To 1,3-dihydro-2H-pyrrolo[2,3-c]pyridin-2-one 9b (12 g, 70.34 mmol, 1.05 eq.) was added to the LiHMDS solution at 1M in THF (281 mL, 281 mmol, 4 eq.) at -78°C. The mixture was stirred at -78°C for 10 min, and warmed to 0°C naturally. After stirring at 0°C for 0.5 h, 1-bromo-2-(2-bromoethoxy)ethane (15.54 g, 66.99 mmol, 1 eq.) was added. The mixture was heated to 20°C and stirred at 20°C for 0.5 h, then refluxed overnight. After cooling to room temperature, the reaction mixture was successively quenched with a 10% NH4Cl solution (300 mL) and extracted with ethyl acetate (2*300 mL). The combined organic layers were washed with brine, dried (Na2SO4), filtered and the solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography (eluent: CH 2 Cl 2 : methanol from 1:0 to 20:1) to give 1.735 g (12% yield) of 2,3,5,6-tetrahydrospiro[ pyran-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one 9c. Intermediate 10c: Synthesis of tert-butyl 2'-oxo-1',2'-dihydrospiro[iperidine-4,3'-pyrrolo[2,3-c]pyridine]-1-carboxylate
Step 1: Synthesis of 1-Benzylspiro[iperidine-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one (intermediate 10a)
[00142] 1,3-Dihydro-2H-pyrrolo[2,3-c]pyridin-2-one hydrochloric acid salt 9b (160 g, 938 mmol, 1 eq.) was added to a solution of Li- 1M HMDS in THF (3751 mL, 3751 mmol, 4 eq.) at -78°C. After heating to 0°C, N-benzyl-2-chloro-N-(2-chloroethyl)ethan-1-amine hydrochloride (218 g, 938 mmol, 1 eq.) was added. The mixture was heated to 20°C, then refluxed overnight. After cooling to room temperature, the reaction mixture was successively quenched with a 10% NH4Cl solution (300 mL) and extracted with ethyl acetate (2*300 mL). The combined organic layers were washed with brine, dried (Na2SO4), filtered and the solvent evaporated in vacuo. The residue was purified by silica gel column chromatography (eluent: CH 2 Cl 2 : methanol from 1:0 to 10:1) to give 70 g (23% yield) of 1-benzylspiro[iperidine-4,3' -pyrrolo[2,3-c]pyridin]-2'(1'H)-one 10a. Step 2: synthesis of spiro[iperidine-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one (intermediate 10b)
[00143] A mixture of 1-benzylspiro[iperidine-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one 10a (70 g, 238.61 mmol, 1 eq. ) in methanol (1000 mL) was hydrogenated at 50°C (50 psi) with 10% Pd/C (50 g) as a catalyst for 15 h. The catalyst was filtered and the solvent was evaporated under vacuum. The residue was purified by flash column chromatography over silica gel (eluent: CH2Cl2/ethyl acetate from 1/0 to 0/1) to give 50 g (93% yield) of spiro[iperidine-4,3'- pyrrolo[2,3-c]pyridin]-2'(1'H)-one 10b. Step 3: Synthesis of tert-butyl 2'-oxo-1',2'-dihydrospiro[iperidine-4,3'-pyrrolo[2,3-c]pyridine]-1-carboxylate (intermediate 10c)
[00144] To a solution of spiro[iperidine-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one 10b (50 g, 246.05 mmol, 1 eq.) in MeOH (1000 mL) was added Boc 2 O (64.43 g, 295.22 mmol, 1.2 eq.). The mixture was stirred at room temperature overnight, then evaporated to dryness. The residue was purified by column chromatography over silica gel (eluent: dichloromethane: ethyl acetate from 1:0 to 0:1) to give 43.32 g (58% yield) of 2'-oxo-1', tert-Butyl 2'-dihydrospiro[iperidine-4,3'-pyrrolo[2,3-c]pyridine]-1-carboxylate 10c. Intermediate 11c: Synthesis of 2,3,5,6-tetrahydrospiro[yran-4,3'-pyrrolo[3,2-c]pyridin]-2'(1'H)-one
Step 1: synthesis of 3,3,7-tribromo-1,3-dihydro-2H-pyrrolo[3,2-c]pyridin-2-one (intermediate 11a)
[00145] Br2 (26 mL, 507 mmol, 4 eq.) was added dropwise to a solution of 1H-pyrrolo[3,2-c]pyridine (15 g, 127 mmol, 1 eq.) in H2O (500 mL) and t-BuOH (500 mL) at room temperature over a period of 20 min. After addition of Br2, the pH of the mixture was approximately 1. Saturated NaHCO3 solution (800 mL) was added slowly and carefully over 30 min, and the pH of the mixture was adjusted to 6.5 - 7. The mixture was stirred for one hour, then filtered. The resulting solid was further washed with water and co-evaporated with ethanol to give 28.5 g (61% yield) of 3,3,7-tribromo-1,3-dihydro-2H-pyrrolo[3,2 -c]pyridin-2-one 11a. Step 2: Synthesis of 1,3-dihydro-2H-pyrrolo[3,2-c]pyridin-2-one hydrobromide (intermediate 11b)
[00146] The reaction was carried out in three parallel reactors. A mixture of 3,3,7-tribromo-1,3-dihydro-2H-pyrrolo[3,2-c]pyridin-2-one 11a (28.5 g, 76.9 mmol, 1 eq.) in ethanol (2850 mL) was hydrogenated at 30°C (50 psi) with Pd/C (14 g) as a catalyst for 3 h. After uptake of H 2 (3 eq.), the catalyst was filtered and the filtrate was evaporated in vacuo to give 14 g (85% yield) of 1,3-dihydro-2H-pyrrolo[3,2- c]pyridin-2-one 11b. Step 3: Synthesis of 2,3,5,6-tetrahydrospiro[yran-4,3'-pyrrolo[3,2-c]pyridin]-2'(1'H)-one (intermediate 11)
[00147] 1,3-Dihydro-2H-pyrrolo[3,2-c]pyridin-2-one hydrobromide 11b (11.7 g, 54.4 mmol, 1.04 eq.) was added to 1M solution of Li-HMDS in THF (210 mL, 210 mmol, 4 eq.) at -78°C. The mixture was stirred at -78°C for 10 min and warmed to 0°C naturally. After stirring at 0°C for 0.5 h, 1-bromo-2-(2-bromoethoxy)ethane (12.1 g, 52.2 mmol, 1 eq.) was added. The mixture was heated to 20°C, then refluxed overnight. The mixture was then cooled to room temperature, quenched with a saturated solution of NH4Cl (200 ml), filtered over a pad of celite and the filtrate extracted with ethyl acetate (2*200 ml). The combined organic layers were washed with brine, dried (Na2SO4), filtered and the solvent evaporated in vacuo. The residue was dissolved in CH2Cl2:methanol (5:1) and purified by column chromatography over silica gel (eluent: CH2Cl2:methanol from 1:0 to 10:1) to give a residue which was further washed with CH3CN to give 812 mg (7% yield) of 2,3,5,6-tetrahydrospiro[yran-4,3'-pyrrolo[3,2-c]pyridin]-2'(1'H)-one 11c. Intermediate 12d: Synthesis of 2,6-dimethyl-2,3,5,6-tetrahydrospiro[yran-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one
Step 1: synthesis of oxybis(propane-2,1-diyl)dimethanesulfonate (intermediate 12b)
[00148] 2,2'-oxybis(propan-1-ol) 12a (obtained from the reduction of diethyl 2,2'-oxydipropionate to LiAlH4 as described in Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), (3), 245-50; 1975) was mesylated using mesyl chloride and triethylamine in isopropyl ether to give oxybis(propane-2,1-diyl)dimethanesulfonate 12b. Diethyl 2,2'-Oxydipropionate was obtained following the procedure reported in Supramolecular Chemistry, 22 (11 & 12), 827-837; 2010, by mixing commercially available ethyl 2-hydroxypropanoate and ethyl 2-bromopropanoate in the presence of NaH in THF. Step 2: synthesis of 1-bromo-2-((1-bromopropan-2-yl)oxy)propane (intermediate 12c)
[00149] To a solution of oxybis(propane-2,1-diyl)dimethanesulfonate 12b in acetone was added LiBr and the reaction mixture was stirred under reflux until completion to give 1-bromo-2-((1-bromopropan) -2-yl)oxy)propane 12c. Step 3: Synthesis of 2,6-dimethyl-2,3,5,6-tetrahydrospiro[yran-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one (intermediate 12d)
[00150] 2,6-dimethyl-2,3,5,6-tetrahydrospiro[yran-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one 12d was synthesized following the protocol used for the synthesis of 2,3,5,6-tetrahydrospiro[yran-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one 9c, using 1-bromo-2-((1-bromopropan-2-yl)oxy)propane 12c instead of 1-bromo-2-(2-bromoethoxy)ethane, and NaH in DMF instead of LiHMDS. Intermediate 13c: Synthesis of 2',3',5',6'-tetrahydrospiro[yrrolo[2,3-c]pyridine-3,4'-thiopyran]-2(1H) 1',1'-dioxide )-one
Step 1: synthesis of bis(2-bromoethyl)sulfan (intermediate 13a)
[00151] To a solution of 2,2'-thiodiethanol (5 g, 40.9 mmol) in dry THF was added phosphorus tribromide (7.75 g, 0.7 eq.) at -15°C under N2 . After stirring for 30 minutes at -15°C the reaction mixture was allowed to warm and stirred for 12 hours at room temperature. It was then diluted with an aq. of NaHCO3 at 0°C. The organic layer was separated, concentrated and purified by column chromatography over silica gel (eluent: petroleum ether/ethyl acetate = 10/1, v/v) to give 2.5 g (22% yield) of bis(2-bromoethyl)sulfan 13a. Step 2: Synthesis of 2',3',5',6'-tetrahydrospiro[yrrolo[2,3-c]pyridine-3,4'-thiopyran]-2(1H)-one (intermediate 13b)
[00152] 2',3',5',6'-tetrahydrospiro[yrrolo[2,3-c]pyridine-3,4'-thiopyran]-2(1H)-one 13b was synthesized following the protocol used for the synthesis of 2,3,5,6-tetrahydrospiro[yran-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one 9c, using bis(2- bromoethyl)sulfan 13a in place of 1-bromo-2-(2-bromoethoxy)ethane, and NaH (4 eq.) in DMF at 0°C in place of LiHMDS. Step 3: Synthesis of 2',3',5',6'-tetrahydrospiro[yrrolo[2,3-c]pyridine-3,4'-thiopyran]-2(1H)-one (intermediate 13c)
[00153] A solution of 2',3',5',6'-tetrahydrospiro[yrrolo[2,3-c]pyridine-3,4'-thiopyran]-2(1H)-one 13b in MeOH/ H2O was oxidized with oxone to give 2',3',5',6'-tetrahydrospiro[yrrolo[2,3-c]pyridine-3,4'-,thiopyran]-2(1H)-one 13c. Intermediate 14d: Synthesis of 3-(methylsulfonyl)propan-1-amine hydrochloride
Step 1: synthesis of 3-(methylsulfonyl)propan-1-ol (intermediate 14a)
[00154] 3-(methylthio)propan-1-ol (200 g, 1900 mmol, CAS 505-10-2) was dissolved in CH2Cl2 (2000 mL). The mixture was cooled to 0°C, then 85% in m-CPBA in water (970 g, 5700 mmol, CAS 937-14-4) was added portion by portion maintaining the temperature between 0 and 5°C. After addition the mixture was allowed to warm to 25°C and stirred for 15 h. The mixture was filtered through a pad of celite and the filtrate was purified by flash column (Eluent: petroleum ether: ethyl acetate = 3:1 and then ethyl acetate: methanol = 10:1) to give the intermediate 14a (75 g, 29%). Step 2: synthesis of 1-bromo-3-(methylsulfonyl)propane (intermediate 14b)
[00155] To a solution of intermediate 14a (75 g, 543 mmol) in CH2Cl2 (750 mL) at 0°C was added phosphorous tribromide (53.6 mL, 570 mmol) dropwise, maintaining the temperature between 0 and 5°C. After addition the mixture was allowed to warm to 25°C and stirred for 15 h. The mixture was poured into ice water, the organic layer was then separated, washed with brine (2 x 500 mL), dried over Na 2 SO 4 , filtered and evaporated in vacuo to give the title compound 14b (77 g, 71%). 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 2.25 - 2.40 (m, 2H) 2.91 (s, 3H) 3.1-3.2 (m, 2H) 3.5- 3.6 (m, 2H). Step 3: synthesis of N-(diphenylmethylene)-3-(methylsulfonyl)propanamine (intermediate 14c)
[00156] To a solution of intermediate 14b (27 g, 134 mmol) in CH3CN (60 mL) was added diphenylmethanimine (27 g, 148 mmol) and DIEA (19.6 g, 152 mmol). The mixture was refluxed for 4 h and then cooled to room temperature. The mixture was then neutralized with 50% aqueous acetic acid at 25°C. Water (80 ml) was added and the mixture was extracted with ethyl acetate (2 X 300 ml). The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated in vacuo. The residue was washed with petroleum ether (4 X 100 mL). The mixture was treated with tert-butyl methyl ether. The solid was collected and washed with petroleum ether. The filtrate was dried under vacuum and the resulting residue was purified by column chromatography (Eluent: CH2Cl2: 1:0 to 10:1 ethyl acetate) to give the title compound 14c (34 g, 85%) as a solid. White. Step 4: Synthesis of 3-(methylsulfonyl)propan-1-amine hydrochloride (intermediate 14d)
[00157] To a solution of intermediate 14c (34 g, 113 mmol) in dioxane (600 mL) was added a 4N HCl/dioxane solution (120 mL, 480 mmol) dropwise at 0 °C. After stirring the mixture was allowed to warm to 25°C and stirred for 15 h. The mixture was filtered. The solid was collected and washed with dioxane to give the title product 14d (11.5 g, 50%) as a yellow powder. Intermediate 15e: Synthesis of 5-Chloro-2-,(chloromethyl)-1-(3-(methylsulfonyl)propyl)-1H-benzo[d]imidazole hydrochloride
Step 1: Synthesis of 4-Chloro-N-(3-(methylsulfonyl)propyl)-2-nitroaniline
[00158] A solution of 1-chloro-4-chloro-3-nitrobenzene (7.6 g, 35 mmols), 3-(methylsulfonyl)propan-1-amine hydrochloride 14d (6 g, 35 mmols) and di- isopropylethylamine (DIEA) (13.5 g, 105 mmol) in ethanol (70 mL) was refluxed for 14 h. The mixture was then cooled to 20°C and the resulting precipitate was filtered and washed with ethanol. 11 g (94%) of intermediate 15a were obtained as an orange powder. Step 2: Synthesis of 4-Chloro-N1-(3-(methylsulfonyl)propyl)benzene-1,2-diamine
[00159] Intermediate 15a (10 g, 29.7 mmol) in methanol (200 mL), EtOAc (200 mL) and THF (200 mL) was hydrogenated with Raney Ni (10 g) as a catalyst at 20 °C. °C (1 atm) for 3 h. After uptake of H 2 (3 eq), the catalyst was filtered off and the filtrate was evaporated. 10 g (90%) of intermediate 15b was obtained as a black solid. Step 3: Synthesis of 5-chloro-2-(diethoxymethyl)-1-(3-(methylsulfonyl)propyl)-1H-benzo[d]imidazole
[00160] Intermediate 15b (10g, 29.7mmols) and methyl dimethoxyacetate (9.2g, 68.31mmols) in 24% by weight KOEt in ethanol (13.5g, 38.5mmols) were stirred and refluxed overnight. The mixture was evaporated under vacuum. Water (200 mL) was then added, followed by acetic acid to neutralize the mixture. The mixture was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with saturated NaHCO3, brine and dried over Na2SO4. The solvent was removed in vacuo to give 12.3 g (90%) of intermediate 15c as a dark oil. Step 4: Synthesis of (5-Chloro-1-(3-(methylsulfonyl)propyl)-1H-benzo[d]imidazol-2-yl)methanol
[00161] Intermediate 15c (12.3 g, 29.3 mmol) in THF (100 mL) was stirred for 0.5 h at 20°C until completely dissolved. conc. (21 mL) and H2O (42 mL) were then added. The mixture was refluxed for 6 h and then cooled to -10°C. CH3OH (50 mL) was added, followed by careful addition of NaBH4 (24 g, 629 mmol). The mixture was stirred for 0.5 h at 10°C and concentrated in vacuo. Water (200 ml) was added. The mixture was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine and dried over Na2SO4. The solvent was removed under vacuum. The resulting solid was washed with ethyl acetate (2 x 5 mL) and dried under vacuum. 6.8 g (60%) of intermediate 15d was obtained as an off-white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 2.20 (dq, J=7.8, 7.5 Hz, 2H), 2.98 (s, 3H), 3.16 - 3.24 (m, 2H), 4.42 (t, J=7.4 Hz, 2H), 4.73 (d, J=6.0 Hz, 2H), 5.73 (t, J=5 .8 Hz, 1H), 7.42 (dd, J=8.7, 1.9 Hz, 1H), 7.63 (d, J=8.5 Hz, 1H), 7.79 - 7.83 (m, 1H). step 5
[00162] To a solution of alcohol 15d (363 mg, 1.414 mmol) in 30 mL of dichloromethane was added dropwise a solution of thionyl chloride (336 mg, 2 eq) in 10 mL of dichloromethane. The reaction mixture was stirred for one hour at 45°C. It was then concentrated to give the desired intermediate 15e (440 mg, 99%) as an HCl salt, which was used as such in the next step. Intermediate 16a: Synthesis of (5-bromo-1-(3-(methylsulfonyl)propyl)-1H-benzo[d]imidazol-2-yl)methanol

[00163] (5-bromo-1-(3-(methylsulfonyl)propyl)-1H-benzo[d]imidazol-2-yl)methanol 16a was synthesized following the chemical route used for the synthesis of (5-chloro -1-(3-(methylsulfonyl)propyl)-1H-benzo[d]imidazol-2-yl)methanol 15d, using 1-bromo-4-fluoro-3-nitrobenzene (7.6 g, 35 mmol) instead of 1-chloro-4-fluoro-3-nitrobenzene in the first step. 6.8 g of the desired product 16a were obtained as an off-white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 2.20 (dq, J=7.8, 7.5 Hz, 2H), 2.98 (s, 3H), 3.16 - 3.24 (m, 2H), 4.42 (t, J=7.4 Hz, 2H), 4.73 (d, J=6.0 Hz, 2H), 5.73 (t, J=5 .8 Hz, 1H), 7.42 (dd, J=8.7, 1.9 Hz, 1H), 7.63 (d, J=8.5 Hz, 1H), 7.79 - 7.83 (m, 1H); m/z = 347 & 349 (M+H)+ Cl standard Intermediate 17b: Synthesis of (5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methanol
Step 1: Synthesis of ethyl 5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indole-2-carboxylate (intermediate 17a)
[00164] Ethyl 5-Bromo-1H-indole-2-carboxylate (2.3 g, 8.6 mmol) was dissolved in DMF (50 mL). The mixture was stirred at room temperature, then 60% suspension of sodium hydride in mineral oil (0.52 g, 12.8 mmol) was added. The resulting mixture was stirred at room temperature for one hour, then 1-bromo-3-(methylsulfonyl)propane 14b (2.6 g, 12.8 mmol) was added. The resulting mixture was stirred at room temperature overnight. The mixture was poured into ice/water solution and extracted with ethyl acetate. The organic layer was dried over MgSO4 and concentrated to give a crude brown oil. The crude was purified by column chromatography using dichloromethane/methanol to give the title compound ethyl 5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indole-2-carboxylate 17a (3.2 g , 96.%) as a white solid. m/z = 344 (M+H)+. Step 2: Synthesis of (5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methanol (intermediate 17b)
[00165] To a solution of intermediate 17a (3.2 g, 8.24 mmol) in THF (100 mL) was added lithium aluminum hydride (2M solution in THF, 5.2 mL, 10 .4 mmol). The resulting mixture was stirred at room temperature overnight. The reaction mixture was quenched by addition of ethyl acetate and ethanol. The resulting mixture was poured into an ice/water solution, then filtered through celite. The aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with brine (100 mL), dried over MgSO4 , filtered and concentrated under reduced pressure. The residue was purified by column chromatography using dichloromethane/methanol as an eluent to give the desired product (5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methanol 17b (2 .5 g, 88%) as a white solid. m/z = 302 (M+H)+. Intermediate 18c: Synthesis of 4-(5-chloro-2-(hydroxymethyl)-1H-indol-1-yl)butanenitrile
Step 1: Synthesis of ethyl 5-chloro-1-(3-cyanopropyl)-1H-indole-2-carboxylate (intermediate 18a)
[00166] Ethyl-5-chloroindole-2-carboxylate (33.55 g, 150 mmol) was dissolved in acetonitrile (600 mL) and stirred at room temperature. Then cesium carbonate (73.31 g, 225 mmol) was added and stirring was continued for 30 minutes. 4-Bromobutyronitrile (18.83 mL, 180 mmol) was added in small portions over a period of one hour and stirring was continued overnight at room temperature. The reaction mixture was filtered and the filtrate was evaporated to dryness. The residue was dissolved in dichloromethane and washed with water. The organic layer was dried over MgSO4 , filtered and evaporated to give 43.5 g (99% yield) of ethyl 5-chloro-1-(3-cyanopropyl)-1H-indole-2-carboxylate 18a, which was used as such in the next step. m/z = 290 (M+H)+. Step 2: Synthesis of 5-Chloro-1-(3-cyanopropyl)-1H-indole-2-carboxylic acid (intermediate 18b)
[00167] Ethyl 5-chloro-1-(3-cyanopropyl)indole-2-carboxylate 18a (43.61 g, 149.97 mmol) was dissolved in 1,4-dioxane (850 mL) and stirred at room temperature. environment. Then, a solution of lithium hydroxide (10.78 g, 450 mmol) in distilled water (150 mL) was added. After stirring overnight at RT, the reaction mixture was evaporated to dryness. The residue was dissolved in 500 ml of water and neutralized with 1N aqueous hydrochloric acid (450 ml). The white precipitate was filtered and dried in vacuo to give 39.8 g (quantitative yield) of 5-chloro-1-(3-cyanopropyl)-1H-indole-2-carboxylic acid 18b. m/z = 262 (M+H)+. Step 3: Synthesis of 4-(5-chloro-2-(hydroxymethyl)-1H-indol-1-yl)butanenitrile (intermediate 18c)
[00168] 5-Chloro-1-(3-cyanopropyl)indole-2-carboxylic acid 18b (39.4 g, 149.98 mmol) and Hunig's base (51.69 mL, 300 mmol) were dissolved in tetra -hydrofuran (550 mL) and stirred at -10°C under an atmosphere of nitrogen. Then, a solution of isobutyl chloroformate in tetrahydrofuran (50 ml) was added dropwise and stirring was continued for one hour at -10°C and one hour at room temperature. Then, sodium borohydride (17.02 g, 450 mmol) was added portionwise at -10°C and stirred for one hour, then distilled water (200 mL) was carefully added to the reaction mixture and stirring was continued. continued for another hour at room temperature under a nitrogen atmosphere. The mixture was neutralized with 10% citric acid in water and then extracted with ethyl acetate. The organic layer was dried over MgSO4 , filtered and evaporated. The residue was purified on silica with heptane/dichloromethane/methanol 50/50/0 -> 0/100/0 -> 0/99/1 as a gradient. The corresponding fractions were evaporated to give 23.9 g (64% yield) of 4-(5-chloro-2-(hydroxymethyl)-1H-indol-1-yl)butanenitrile 18c as a white powder. m/z = 248 (M+H)+. Intermediate 19b: Synthesis of (5-Chloro-1-(4,4,4-trifluorobutyl)-1H-imidazo[4,5-b]pyridin-2-yl)methanol
Step 1: 6-Chloro-N3-(4,4,4-trifluorobutyl)-pyridine-2,3-diamine (intermediate 19a)
[00169] 6-Chloropyridine-2,3-diamine (5 g, 34.82 mmol) was dissolved in dichloromethane (200 mL), acetic acid (20 drops) and 4,4,4-trifluorobutanal (4.38 g, 34.8 mmol) were added. The resulting mixture was stirred for 30 minutes and then sodium triacetoxyhydroborate (22.14 g, 104.5 mmol) was added. The reaction mixture was stirred at room temperature overnight and a 50% Na2CO3 solution was added dropwise until gas evolution had stopped. The organic layer was separated, dried over MgSO4 , filtered and evaporated to dryness. The residue was purified by column chromatography using heptane/EtOAc 7/3 to pure EtOAc. Intermediate 6-chloro-N3-(4,4,4-trifluorobutyl)-pyridine-2,3-diamine 19a was recovered as a white solid and dried in vacuo overnight (6.16 g, 70%). m/z = 254 (M+H)+. Step 2: Synthesis of (5-chloro-1-(4,4,4-trifluorobutyl)-1H-imidazo[4,5-b]pyridin-2-yl)methanol (intermediate 19b)
[00170] A mixture of intermediate 19a (5.68 g, 22.46 mmol) and 2-hydroxyacetic acid (4.27 g, 56.2 mmol) was stirred at 150°C for 4 hours. The mixture was allowed to cool to room temperature and treated carefully with 3N hydrochloric acid. The resulting mixture was basified with aqueous ammonia and extracted with CH2Cl2 (300 mL). The organic layer was dried over MgSO4 and evaporated to dryness. The residue was purified by column chromatography on silica using CH 2 Cl 2 in EtOAc to give 4.27 g (65%) of (5-chloro-1-(4,4,4-trifluorobutyl)-1H-imidazo[4,5- b]pyridin-2-yl)methanol 19b as a brown solid. m/z = 294 (M+H)+. 1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.00 (s, 2H), 1.12 - 1.23 (m, 2H), 1.83 - 1.99 (m, 2H ), 2.12 - 2.31 (m, 2H), 2.91 (spt, J=3.50 Hz, 1H), 4.38 - 4.54 (m, 2H), 5.38 (s, 2H), 7.13 (dd, J=5.27, 0.50Hz, 1H), 7.27 (d, J=8.28Hz, 1H), 7.61 (d , J=8.53 Hz, 1H), 8.36 (d, J=5.27 Hz, 1H), 8.77 (s, 1H). Intermediate 20e: Synthesis of (5-chloro-1-(4-fluorobutyl)-1H -pyrrolo[3,2-b]pyridin-2-yl)methanol
Step 1: Synthesis of 2-bromo-6-chloropyridin-3-amine (intermediate 20a)
[00171] Bromine (24.86 g, 155.57 mmol) was added to a solution of 6-chloropyridin-3-amine (20.00 g, 155.57 mmol) and sodium acetate (25.52 g, 311 .14 mmol) in acetic acid (383 mL). The reaction mixture was stirred at room temperature for one hour. Acetic acid was then evaporated. The residue was dissolved in EtOAc, washed with saturated aqueous Na2CO3, water and brine. The organic layer was dried over MgSO4 , filtered and evaporated, yielding 32.20 g of the desired product 20a (99.8%). m/z = 206.96 (M+H)+, standard Cl + Br. Step 2: Synthesis of 5-Chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (intermediate 20b)
[00172] 2-oxopropanoic acid (36.22 g, 411.31 mmol), palladium (II) acetate (7.74 g, 34.15 mmol) and Et3N (69.11 g, 682.94 mmol) were added to a solution of 2-bromo-6-chloropyridin-3-amine 20a (32.20 g, 155.21 mmol) and TPP (35.83 g, 136.59 mmol) in dry DMF (300 mL). The reaction mixture was stirred at 100°C overnight. The solvent was then evaporated, water was added and the water layer was washed with EtOAc. The water layer was acidified with conc. The precipitate was filtered and dried, yielding 25.21 g of the desired product 20b (82.6%). m/z = 197.1 (M+H)+, Cl standard. Step 3: Synthesis of methyl 5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylate (intermediate 20c)
[00173] 5-Chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid 20b (25.20 g, 128.18 mmol) was added to a refluxing mixture of sulfuric acid (20 mL) and methanol (400 mL). The mixture was refluxed overnight. The mixture was then evaporated and a cold solution of NaHCO3 was added until basic pH. The precipitate was filtered and dried, yielding 16.15 g of the desired product 20c (59.8%). m/z = 211.17 (M+H)+, Cl standard. Step 4: Synthesis of methyl 5-chloro-1-(4-fluorobutyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate (intermediate 20d)
[00174] To a solution of methyl 5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylate 20c (2.9 g, 12.2 mmol) in DMF (50 mL) was successively added carbonate of cesium (4 g, 12.2 mmol) and 1-bromo-4-fluorobutane (1.3 mL, 12.2 mmol). The resulting mixture was stirred at 60°C overnight. The reaction mixture was allowed to cool to room temperature, then poured into ice water and the product extracted 3 times with DCM. The combined organic layers were dried over Na2SO4, filtered and evaporated to give the target product 20d as a yellowish solid. The product was used as such in the next step. m/z = 313 (M+H)+, Cl standard. Step 5: Synthesis of (5-Chloro-1-(4-fluorobutyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)methanol (intermediate 20e)
[00175] To a solution of methyl 5-chloro-1-(4-fluorobutyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate 20d (3.82 g, 10.8 mmol) in THF (100 mL) was added a 1M solution of lithium aluminum hydride (11.96 mL, 11.96 mmol) at -75°C. The cooling bath was then removed and the reaction mixture was kept at room temperature for 3 hours. EtOAc was added, followed by a saturated solution of NH4Cl. The mixture was stirred for 30 min. The organic layer was dried over Na2SO4, filtered and evaporated to give a yellow oil, which was purified by column chromatography to give the target product (5-chloro-1-(4-fluorobutyl)-1H-pyrrolo[3,2- b]pyridin-2-yl)methanol 20e (2.8 g, 98%). m/z = 257 (M+H)+, Cl standard. Intermediates 21b and 21c: Synthesis of 4-(5-chloro-2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl)butanenitrile (intermediate 21b) and 4-(6-chloro-2-(hydroxymethyl) )-1H-benzo[d]imidazol-1-yl)butanenitrile (intermediate 21c)
Step 1: Synthesis of (5-chloro-1H-benzo[d]imidazol-2-yl)methanol (intermediate 21a)
[00176] A mixture of 4-chlorobenzene-1,2-diamine (105 g, 736 mmol, 1 eq.) and hydroxyacetic acid (112 g, 2 eq.) in xylene (1500 mL) was stirred at 150°C for 4 hours. The mixture was then cooled to 60°C and treated with 3N HCl (480 mL), then basified to pH = 7 - 8 by the addition of aqueous ammonia. The mixture was filtered and the solid was collected, washed with H2O and tert-butyl methyl ether to give 123 g (82% yield) of (5-chloro-1H-benzo[d]imidazol-2-yl)methanol 21st Step 2: Synthesis of 4-(5-chloro-2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl)butanenitrile (intermediate 21b) and 4-(6-chloro-2-(hydroxymethyl)-1H -benzo[d]imidazol-1-yl)butanenitrile (intermediate 21c)
[00177] A mixture of (5-chloro-1H-benzo[d]imidazol-2-yl)methanol 21a (500 mg, 2.738 mmol, 1 eq.), 4-bromobutyronitrile (466 mg, 1.15 eq.) , cesium carbonate (1.338 g, 1.5 eq.) and potassium iodide (45 mg, 0.1 eq.) in acetonitrile (5 mL) was refluxed overnight. The mixture was then cooled and filtered. The filtrate was evaporated in vacuo and the residue treated with ethyl acetate (30ml) and brine (20ml). The separated organic layer was dried (Na2SO4), filtered and the solvent evaporated in vacuo. The residue was purified by column chromatography (eluent: CH2Cl2:methanol from 1:0 to 15:1) to give 732 mg (54%) of a mixture containing the two regioisomers 21b and 21c in a 1/1 ratio. This mixture was further separated by SFC to provide the pure 21b regioisomer. Intermediate 22c: Synthesis of 3-aminospiro[cyclobutane-1,3'-indolin]-2'-one
Step 1
[00178] To alcohol 4c or 4d (5 g, 26.425 mmol) in DCM was added Dess-Martin periodinane (16.8 g, 1.5 eq) at 0°C. After 16 h at RT, the MR was filtered and a saturated solution of NaHCO3 (50 mL) and a solution of NaS2O3 (50 mL) were added. After stirring for 30 minutes, the organic layer was separated, dried over Na2SO4, and concentrated in vacuo to provide the desired spiro[cyclobutane-1,3'-indoline]-2',3-dione 22a as a racemic mixture, which was used without further purification in the next step. step 2
[00179] A mixture of ketone 22a (2 g, 10.68 mmol), sodium carbonate (3.397 g, 3 eq) and hydroxylamine hydrochloride (1.485 g, 2 eq) in EtOH/H2O (1/1, 100 mL ) was heated at 100°C for one hour. The MR was then concentrated in vacuo and the resulting precipitate was filtered, washed with water and dried in a vacuum oven to give 3-(hydroxyimino)spiro[cyclobutane-1,3'-indolin]-2'-one 22b (1.5 g, 69% yield). step 3
[00180] Oxime 22b was hydrogenated over RaNi (435 mg, 1 eq) in 7N NH 3 in MeOH (50 mL) overnight. The solution was then filtered over decalite and concentrated in vacuo. The crude was then triturated in Et2O, and the resulting solid was filtered and oven dried to give aminospiro[cyclobutane-1,3'-indolin]-2'-one 22c (1.3 g, 85% yield) as a mixture of two isomers. Synthesis of final compounds Compound 1 Synthesis of 1'-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-2'-oxo-1',2' tert-butyl -dihydro-1H-spiro[iperidine-4,3'-pyrrolo[2,3-c]pyridine]-1-carboxylate

[00181] To a suspension of {5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methanol 17b (4000 mg, 13.25 mmol), 2'-oxo-1' tert-Butyl ,2'-dihydro-1H-spiro[iperidine-4,3'-pyrrolo[2,3-c]pyridine]-1-carboxylate 10c (4423 mg, 14.58 mmol) and TPP ( 4172 mg, 15.91 mmol) in dry THF (92 mL) was added DIAD (3.869 mL, 19.88 mmol) at room temperature and the reaction mixture was stirred overnight. THF was evaporated and the crude was purified by column chromatography. After evaporating the relevant fractions, the residue was recrystallized from water. The crystals formed were filtered and washed with some water and heptane to give the title product 1 as a beige powder (1231 mg, Yd = 15.8%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.45 (s, 9H) 1.80 (t, J=5.50 Hz, 4H) 2.03 - 2.16 (m, 2H) 3.01 (s, 3H) 3.14 - 3.25 (m, 2H) 3.60 - 3.83 (m, 4H) 4.37 (t, J=7.48 Hz, 2H ) 5.20 (s, 2H) 6.37 (s, 1H) 7.16 (dd, J=8.69, 2.09 Hz, 1H) 7.53 (d, J=1.98 Hz, 1H) 7.55 (d, J=8.80 Hz, 1H) 7.69 (d, J=4.62 Hz, 1H) 8.33 (d, J=4.84 Hz, 1H) 8.39 (s, 1H); m/z = 587.23 (M+H)++Cl standard Compound 2: Synthesis of 1'-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl} methyl)spiro[iperidine-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one

[00182] To a solution of 1'-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)2'-oxo-1',2'-di- tert-butyl hydro-1H-spiro[iperidine-4,3'-pyrrolo[2,3-c]pyridine]-1-carboxylate 1 (3.39 g, 3.75 mmol) in DCM (20 mL) was TFA (2.872 mL, 37.53 mmol) was added and the mixture was stirred overnight at room temperature. Then water was added and the reaction mixture was basified with Na2CO3 solution. The DCM was evaporated and the remaining aqueous suspension was stirred for 3 hours. The solid was filtered, washed with water and then purified by column chromatography to obtain a pink glassy oil. The product was triturated in diethyl ether to give the desired product 2 as a pink powder which was dried in a vacuum oven (466 mg, 23.7%); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.62 - 1.88 (m, 4H) 2.02 - 2.18 (m, 2H) 2.93 - 3.07 (m, 5H ) 3.11 - 3.24 (m, 4H) 4.38 (t, J=7.48 Hz, 2H) 5.19 (s, 2H) 6.33 (s, 1H) 7, 16 (dd, J=8.69, 2.09Hz, 1H) 7.50 - 7.58 (m, 2H) 7.64 (d, J=4.84Hz, 1H) 8.29 - 8.42 (m, 2H); m/z = 487.27 (M+H)++Cl standard Compound 3: Synthesis of 1'-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl} methyl)-1-(methylsulfonyl)spiro[iperidine-4,3'-pyrrolo[2,3-c]pyridin]-2'(1'H)-one

[00183] 1'-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)spiro[iperidine-4,3'-pyrrolo[2,3-c ]pyridin]-2'(1'H)-one 2 (500 mg, 0.72 mmol) was dissolved in DCM (5 mL), then methanesulfonyl chloride (0.11 mL, 1.44 mmol) and Et3N (0.30 mL, 2.16 mmol) was added. The mixture was stirred at room temperature for 30 minutes. Water was added and the reaction mixture was basified with NaHCO3 solution. The product was extracted with DCM (2 times). The combined organic layers were dried over MgSO4 , filtered and evaporated. The residue was purified by preparative column chromatography to give the desired product 3 (172 mg, Yd = 42.4%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.88 - 2.16 (m, 6H) 3.00 (s, 3H) 3.01 (s, 3H) 3.17 - 3.26 (m, 2H) 3.41 - 3.51 (m, 2H) 3.52 - 3.64 (m, 2H) 4.38 (t, J=7.48Hz, 2H) 5, 20 (s, 2H) 6.38 (s, 1H) 7.16 (dd, J=8.69, 2.09 Hz, 1H) 7.53 (d, J=1.98 Hz, 1 H) 7.56 (d, J=8.80 Hz, 1H) 7.70 (d, J=4.84 Hz, 1H) 8.36 (d, J=4.84 Hz, 1H) 8.41 (s, 1H); m/z = 565.03 (M+H)++Cl standard Compound 4: Synthesis of 1'-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl} tert-butyl methyl)-2'-oxo-1',2'-dihydro-1H-spiro[azetidine-3,3'-indole]-1-carboxylate

[00184] Tert-Butyl 2'-oxo-1',2'-dihydro-1H-spiro[azetidine-3,3'-indole]-1-carboxylate 3f (1000 mg, 3.65 mmol) was dissolved in dry DMF (23 mL), then 5-chloro-2-(chloromethyl)-1-[3-(methylsulfonyl)propyl]-1H-benzimidazole 15e hydrochloric acid (1304 mg, 3.64 mmol) and carbonate of cesium (3563 mg, 3.56 mmol) were added. The reaction mixture was stirred at room temperature overnight. Ice water was added and the mixture was stirred overnight. The solid formed was filtered and washed with water and a little ether. After drying in the vacuum oven, the desired product 4 was obtained as a pink solid (1695 mg, Yd = 81.5%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.44 (s, 9H) 2.10 - 2.21 (m, 2H) 3.00 (s, 3H) 3.19 - 3.25 (m, 2H) 4.03 - 4.19 (m, 4H) 4.47 (t, J=7.48Hz, 2H) 5.22 (s, 2H) 7.13 (td, J=7.48, 0.88 Hz, 1H) 7.19 (d, J=7.70 Hz, 1H) 7.27 - 7.34 (m, 2H) 7.65 - 7.69 (m, 3H); m/z = 559.21 (M+H)++Cl standard Compound 5: Synthesis of 1'-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl} methyl)spiro[azetidine-3,3'-indole]-2'(1'H)-one

[00185] To a solution of 1'-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-2'-oxo-1',2'-di tert-butyl -hydro-1H-spiro[azetidine-3,3'-indole]-1-carboxylate 4 (1.5 g, 2.63 mmol) in DCM (20 mL) was added TFA (1 mL, 5 eq.) at TA. After 12 hours more TFA (2 ml) was added and the mixture was stirred for 24 hours. The reaction was then neutralized by a solution of Na2CO3. The DCM was evaporated and the solid formed was filtered and washed with water and ether to give the TFA salt of the desired product 5 as a gray powder (1.303 g, Yd = 86.5%). 1H NMR (400 MHz, DMSO-d6) δ ppm 2.11 - 2.26 (m, 2H) 3.01 (s, 3H) 3.19 - 3.28 (m, 2H) 4.16 - 4.35 (m, 4H) 4.48 (t, J=7.48 Hz, 2H) 5.22 (s, 2H) 7.18 - 7.28 (m, 2H) 7, 32 (dd, J=8.80, 1.98 Hz, 1H) 7.36 (td, J=7.90, 0.88 Hz, 1H) 7.66 (d, J=1.98 Hz , 1H) 7.69 (d, J=8.80 Hz, 1H) 7.85 (d, J=6.82 Hz, 1H) 9.27 (sl, 2H); m/z = 459.18 (M+H)++Cl standard Compound 6: Synthesis of 1'-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl} methyl)-1-(2-hydroxy-2-methylpropanoyl)spiro[azetidine-3,3'-indol]-2'(1'H)-one

[00186] A 1'-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)spiro[azetidine-3,3'-indol]-2'(1 'H)-one 5 (300 mg, 0.50 mmol), 2-hydroxy-2-methylpropanoic acid (117 mg, 1.12 mmol) and Et3N (0.482 mL, 2.80 mmol) were stirred vigorously at room temperature. in dry DMF (4 mL), while DECP (0.188 mL, 1.12 mmol) was added dropwise. Stirring was continued for one hour at room temperature in a closed vessel. Some ice was added followed by a saturated solution of sodium bicarbonate. The resulting suspension was stirred for two hours and the solid was filtered and further purified by column chromatography eluting with a gradient of DCM and MeOH. All pure fractions were evaporated to give a yellowish foam which was further triturated in ether and filtered to give the title product 6 (121 mg, Yd = 42.0%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.31 (s, 3H) 1.33 (s, 3H) 2.11 - 2.24 (m, 2H) 3.00 (s, 3 H) 3.18 - 3.27 (m, 2H) 4.02 - 4.20 (m, 2H) 4.47 (t, J=7.37Hz, 2H) 4.55 - 4, 75 (m, 2H) 5.23 (s, 2H) 5.25 (s, 1H) 7.11 - 7.23 (m, 2H) 7.27 - 7.35 (m, 2H) ) 7.60 - 7.65 (m, 1H) 7.65 - 7.71 (m, 2H); m/z = 545.41 (M+H)++Cl standard Compound 7: Synthesis of 1'-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl} methyl)-1-(pyridin-3-yl)spiro[azetidine-3,3'-indol]-2'(1'H)-one

[00187] A mixture of 1'-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)spiro[azetidine-3,3'-indole]-2'(1'H)-one 5 (259 mg, 0.43 mmol) and 3-bromopyridine (0.084 mL, 0.87 mmol) in toluene (1.5 mL) was degassed with nitrogen gas for 5 minutes. Then Pd2(dba)3 (10mg, 0.01mmol), NaOtBu (52mg, 0.54mmol) and BINAP (20mg, 0.03mmol) were added. The mixture was degassed again and then heated in a μ wave oven for two hours at 125°C. The reaction mixture was evaporated, taken up in water and extracted with DCM. Some insolubles were filtered out. The two phases were separated and the organic layer was dried over Na2SO4, filtered and evaporated to dryness. The crude was purified by preparative column chromatography to give the title product 7 (35 mg, Yd = 15.0%). 1H NMR (400 MHz, DMSO-d6) δ ppm 2.09 - 2.21 (m, 2H) 3.00 (s, 3H) 3.19 - 3.27 (m, 2H) 4.13 - 4.27 (m, 4H) 4.47 (t, J=7.48 Hz, 2H) 5.26 (s, 2H) 6.99 (ddd, J=8.25, 2.75 , 1.32 Hz, 1H) 7.12 - 7.17 (m, 1H) 7.20 (d, J=7.70Hz, 1H) 7.25 (dd, J=8.14, 4.62 Hz, 1H) 7.28 - 7.36 (m, 2H) 7.64 - 7.71 (m, 3H) 7.98 (d, J=2.64Hz, 1H) 8.02 (dd, J=4.62, 1.32 Hz, 1H); m/z = 536.07 (M+H)++Cl standard Compound 8: Synthesis of 1'-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl} methyl)-1-(2-hydroxy-2-methylpropyl)spiro[azetidine-3,3'-indol]-2'(1'H)-one

[00188] To a solution of 1'-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)spiro[azetidine-3,3'-indole]-2 '(1'H)-one 5 (150 mg, 0.33 mmol) in EtOH (20 mL) and DMF (5 mL) were added Et 3 N (0.227 mL, 1.63 mmol) and 2,2-dimethyloxirane (0.087 mL). mL, 0.98 mmol). The reaction mixture was heated at 60°C for 40 hours. Heating was stopped and ice water was added. The EtOH was evaporated. The solid formed was filtered and washed with water and ether to obtain a gray powder. The crude was purified by column chromatography to obtain the title product 8 as a white solid after drying in a vacuum oven (74 mg, Yd = 39.2%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.12 (s, 6H) 2.06 - 2.17 (m, 2H) 2.46 (s, 2H) 2.99 (s, 3 H) 3.17 - 3.25 (m, 2H) 3.54 (q, J=7.04Hz, 4H) 4.12 (s, 1H) 4.45 (t, J=7, 37 Hz, 2H) 5.21 (s, 2H) 7.10 - 7.17 (m, 2H) 7.23 - 7.28 (m, 1H) 7.30 (dd, J=8 .58, 1.98 Hz, 1H) 7.64 - 7.68 (m, 2H) 7.73 - 7.77 (m, 1H); m/z = 531.09 (M+H)++Cl standard Compound 9: Synthesis of 1'-[[5-chloro-1-(3-methylsulfonylpropyl)benzimidazol-2-yl]methyl]-1-(2 ,2,2-trifluoroethyl)spiro[azetidine-3,3'-indoline]-2'-one

[00189] A solution of 1'-[[5-chloro-1-(3-methylsulfonylpropyl)benzimidazol-2-yl]methyl]spiro[azetidine-3,3'-indoline]-2'-one 5 (573 mg , 1 mmol), 2,2,2-trifluoroethyl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate (382 mg, 1 mmol) and N-ethyl-N- isopropyl-propan-2-amine (0.52 mL, 3 mmol) was stirred in dioxane (10 mL) at 50°C over the weekend. The reaction mixture was allowed to cool to room temperature. The mixture was evaporated to dryness and the residue was recrystallized from 100/1 ethanol/acetonitrile. The off-white crystals were collected by filtration and dried in vacuo to give the title compound 9 (420 mg, 77%). 1H NMR (360 MHz, DMSO-d6) δ ppm 2.13 (m, J=8.1 Hz, 2H), 3.00 (s, 3H), 3.22 (m, J=15.4 Hz, 2H), 3.42 (q, J=10.0 Hz, 2H), 3.64 (d, J=7.0 Hz, 2H), 3.75 (d, J=7, 0 Hz, 2H), 4.46 (t, J=7.1 Hz, 2H), 5.22 (s, 2H), 7.07 - 7.22 (m, 2H), 7. 31 (d, J=8.8 Hz, 1H), 7.27 (d, J=7.3 Hz, 1H), 7.62 - 7.79 (m, 3H); m/z = 540.99 (M+H)+ Cl standard; melting point: 200.68°C. Compound 12: Synthesis of (1R,3R)-1'-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-benzo[d]imidazol-2-yl)methyl)-3-hydroxyspiro [cyclobutane-1,3'-indolin]-2'-one

[00190] (3R)-1'-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-3-hydroxyspiro[cyclobutane-1,3'-indole ]-2'(1'H)-one 12 was synthesized following the reaction conditions used for the synthesis of compound 4, using (3R)-hydroxyspiro[cyclobutane-1,3'-indolin]-2'-one 4d instead of tert-butyl 2'-oxo-1',2'-dihydro-1H-spiro[azetidine-3,3'-indole]-1-carboxylate 3f and was obtained as a slightly pink solid, with a yield of 82%. 1H NMR (400 MHz, DMSO-d6) δ ppm 2.08 - 2.21 (m, 2H) 2.27 - 2.38 (m, 2H) 2.60 - 2.72 (m, 2H ) 2.99 (s, 3H) 3.19 - 3.27 (m, 2H) 4.46 (t, J=7.48 Hz, 2H) 4.50 - 4.62 (m, 1 H) 5.20 (s, 2H) 5.45 (d, J=6.82Hz, 1H) 7.05 - 7.14 (m, 2H) 7.18 - 7.25 (m, 1H) 7.30 (dd, J=8.80, 1.98 Hz, 1H) 7.45 - 7.55 (m, 1H) 7.63 - 7.71 (m, 2H); m/z = 474.05 (M+H)+; mp = 209.84°C. Compound 104: Synthesis of (1R,3R)-1'-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-benzo[d]imidazol-2-yl)methyl)-2' methylcarbamate - oxospiro[cyclobutane-1,3'-indoline]-3-yl

[00191] A solution of (3R)-1'-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-3-hydroxyspiro[cyclobutane-1,3 '-indol]-2'(1'H)-one 12 (100 mg, 0.205 mmol), triethylamine (0.142 mL, 1.023 mmol) and N,N'-disuccinimidyl carbonate (210 mg, 0.82 mmol) in DCM (1.5 mL) was stirred at RT for two hours. A 2M methylamine solution (1.54 mL, 3.07 mmol) was then added and the MR was further stirred for 30 minutes. It was then concentrated and the residue was purified by silica gel chromatography using a gradient of MeOH (0 to 5%) in DCM to give 110 mg (99% yield) of 1'-({5-chloro-1 -[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-2'-oxo-1',2'-dihydrospiro[cyclobutane-1,3'-indol]-3-yl 104 as a slightly pink solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 2.16 (quin, J=7.59 Hz, 2H) 2.45 - 2.52 (m, 2H) 2.59 (d, J=4 .62 Hz, 3H) 2.73 - 2.82 (m, 2H) 3.00 (s, 3H) 3.20 - 3.27 (m, 2H) 4.47 (t, J= 7.37 Hz, 2H) 5.22 (s, 2H) 5.25 - 5.35 (m, 1H) 7.07 - 7.16 (m, 3H) 7.22 - 7.28 (m, 1H) 7.28 - 7.33 (m, 1H) 7.48 - 7.54 (m, 1H) 7.64 - 7.70 (m, 2H); m/z = 531.15 (M+H)+. Compound 117: Synthesis of N-[(1'-{[5-Chloro-1-(3-cyanopropyl)-1H-indol-2-yl]methyl}-2'-oxo-1',2'-di -hydro-1H-spiro[azetidine-3,3'-indol]-1-yl)sulfonyl]acetamide.

[00192] A mixture of 4-{5-Chloro-2-[(2'-oxospiro[azetidine-3,3'-indol]-1'(2'H)-yl)methyl]-1H-indol-1 -yl}butanenitrile 59 (588 mg, 1.133 mmol) and sulfamide (326 mg, 3.4 mmol) in dioxane (20 mL) was stirred in a microwave oven at 160°C for 40 minutes. After cooling, the MR was concentrated in vacuo and the residue was recrystallized from methanol. This crude material (212 mg, 0.438 mmol) was then redissolved in DCM (30 mL) and acetic anhydride (82 µL, 0.876 mmol), N-methylmorpholine (96 µL, 0.876 mmol) and DMAP (3.7 mg, 0 .03 mmol) were added. After 3 hours at RT, two more equivalents of acetic anhydride and N-methylmorpholine were added and the MR was stirred overnight. It was then quenched with MeOH (1 mL) and concentrated in vacuo. The resulting residue was purified by silica gel chromatography using a gradient of MeOH (0 to 5%) in DCM to give 140 mg (58% yield) of N-[(1'-{[5-Chloro- 1-(3-cyanopropyl)-1H-indol-2-yl]methyl}-2'-oxo-1',2'-dihydro-1H-spiro[azetidine-3,3'-indole]-1- yl)sulfonyl]acetamide 117 as a white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.93 - 2.04 (m, 1H), 2.16 (s, 3H), 2.58 (t, J=7.4 Hz, 2 H), 4.25 (d, J=8.1 Hz, 2H), 4.27 - 4.35 (m, 2H), 4.40 (d, J=8.4Hz, 2H) , 5.12 (s, 2H), 6.38 (s, 1H), 7.08 (d, J=7.9Hz, 1H), 7.11 - 7.21 (m, 2H ), 7.26 - 7.35 (m, 1H), 7.48 - 7.55 (m, 2H), 7.58 (d, J=7.0Hz, 1H), 10.84 - 10.85 (m, 0H), 11.75 (sl, 2H); m/z = 524 (MH)-; mp = 182.85°C. Compound 115: Synthesis of (1'-{[5-chloro-1-(3-cyanopropyl)-1H-benzimidazol-2-yl]methyl}-2'-oxo-1',2'-dihydro-1H -spiro[iperidine-4,3'-pyrrolo[2,3-c]pyridin]-1-yl)diethyl phosphonate

[00193] A mixture of 4-(5-Chloro-2-((2'-oxospiro[iperidine-4,3'-pyrrolo[2,3-c]pyridin]-1'(2'H)-hydrochloride) yl)methyl)-1H-benzo[d]imidazol-1-yl)butanenitrile 84 (500 mg, 0.985 mmol), diethoxy cyanophosphonate (0.448 mL, 3 eq) and triethylamine (0.411 mL, 3 eq) in DMF (10 mL) was stirred at RT for two hours. The mixture was then extracted with DCM and washed with water. The organics were then dried over MgSO4, concentrated in vacuo and purified by chromatography on silica gel using a gradient of MeOH (0 to 10%) in DCM, followed by a Prep HPLC purification (Stationary phase: RP Vydac Denali C18 - 10 μm, 200 g, 5 cm, Mobile phase: 0.25% NH4HCO3 solution in water, CH3CN), to give 320 mg (56% yield) of (1'-{[5-Chloro-1- (3-cyanopropyl)-1H-benzimidazol-2-yl]methyl}-2'-oxo-1',2'-dihydro-1H-spiro[iperidine-4,3'-pyrrolo[2,3-c ]pyridine]-1-yl)diethyl)phosphonate 115. m/z = 571 (M+H)+. Compounds 148 and 149: Synthesis of 4-(2-(((1r,3r)-3-amino-2'-oxospiro[cyclobutane-1,3'-indolin]-1'-yl)methyl)-5-chloro -1H-benzo[d]imidazol-1-yl)butanenitrile and 4-(2-(((1s,3s)-3-amino-2'oxospiro[cyclobutane-1,3'-indolin]-1'-yl )methyl)-5-chloro-1H-benzo[d]imidazol-1-yl)butanenitrile

[00194] To a solution of amine 22c (194 mg, 1.035 mmol) in dry DMF (10 mL) was added sodium hydride (79 mg, 2 eq) at RT. After 30 minutes, 4-(5-chloro-2-(chloromethyl)-1H-benzo[d]imidazol-1-yl)butanenitrile hydrochloric acid (332 mg, 1 eq) was added and the MR was stirred at RT for two hours. The crude was then filtered and the filtrate was concentrated in vacuo. The resulting crude was further purified by preparative SFC (Stationary phase: Chiralcel Diacel OJ 20 x 250 mm, Mobile phase: CO2, iPrOH with 0.02% iPrNH2 ), to give the pure isomers 148 (85 mg, 19% yield ) and 149 (158 mg, 35% yield).
[00195] For 148: 1H NMR (400 MHz, DMSO-d6) δ ppm 1.91 - 2.10 (m, 2H) 2.13 - 2.27 (m, 2H) 2.55 - 2, 71 (m, 4H) 3.78 (quin, J=8.03Hz, 1H) 4.38 (t, J=7.59Hz, 2H) 5.20 (s, 2H) 7, 08 (td, J=8.10, 1.54Hz, 2H) 7.20 (td, J=7.70, 1.32Hz, 1H) 7.29 (dd, J=8.58, 1.98 Hz, 1H) 7.53 - 7.70 (m, 3H); m/z = 420 [M+H]+. For 149: 1H NMR (400 MHz, DMSO-d6) δ ppm 1.80 - 2.20 (m, 4H) 2.20 - 2.34 (m, 2H) 2.36 - 2.47 (m , 2H) 2.59 (t, J=7.48 Hz, 2H) 3.77 - 3.95 (m, 1H) 4.36 (t, J=7.50 Hz, 2H) 5 .21 (s, 2H) 7.00 - 7.14 (m, 2H) 7.16 - 7.25 (m, 1H) 7.29 (dd, J=8.58, 1.98 Hz , 1H) 7.55 (d, J=6.82 Hz, 1H) 7.64 (d, J=8.80 Hz, 1H) 7.66 (d, J=1.76 Hz, 1 H). Compounds 143 and 144: Synthesis of 1-((1s,3s)-1'-((5-chloro-1-(3-cyanopropyl)-1H-benzo[d]imidazol-2-yl)methyl)-2'-oxospiro[cyclobutane-1,3'-indolin]-3-yl)-3-isopropylurea and 1-((1r,3r)-1'-((5-chloro-1-(3-cyanopropyl)-1H- benzo[d]imidazol-2-yl)methyl)-2'-oxospiro[cyclobutane-1,3'-indolin]-3-yl)-3-isopropylurea.

[00196] A mixture of 4-(2-(3-amino-2'-oxospiro[cyclobutane-1,3'-indolin]-1'-yl)methyl)-5-chloro-1H-benzo[d]imidazole -1-yl)butanenitrile (racemic mixture, 500 mg, 1.191 mmol), 2-isocyanatopropane (0.14 mL, 1.2 eq) and DIPEA (3.175 mL, 2 eq) was stirred at RT for one hour. The MR was then concentrated in vacuo and purified by preparative HPLC (Stationary phase: RP Vydac Denali C18 - 10 μm, 200 g, 5 cm, Mobile phase: 0.25% NH4HCO3 solution in water, CH3CN) to give the mixture of enantiomers, which were subsequently separated by preparative SFC (Stationary phase: Chiralpak Diacel AD 30 x 250 mm), Mobile phase: CO2, MeOH with 0.2% iPrNH2, giving 240 mg (40% yield) of 143 and 122 mg (20% yield) of 144.
[00197] The compounds in the following table were synthesized according to the protocols described above, and with methods known in the art to the skilled chemist.




















































antiviral activity
[00198] Black 96-well clear bottom microtiter plates (Corning, Amsterdam, The Netherlands) were filled in duplicate using a custom robot system with serial 4-fold dilutions of compound in a final volume of 50 μL of culture medium [RPMI medium without phenol red, 10% FBS, 0.04% gentamicin (50 mg/ml) and 0.5% DMSO]. Then, 100 μL of a suspension of HeLa cells (5 x 10 4 cells/mL) in culture medium was added to each well followed by the addition of 50 μL of rgRSV224 virus (MOI = 0.02) in culture medium using a dispenser. of multidrops (Thermo Scientific, Erembodegem, Belgium). The rgRSV224 virus is an engineered virus that includes an additional GFP gene (Hallak et al., 2000) and has been approved by the NIH (Bethesda, MD, USA). Medium, virus-infected and mock-infected controls were included in each test. Cells were incubated at 37°C in a 5% CO2 atmosphere. Three days post-exposure to the virus, viral replication was quantified by measuring GFP expression in the cells by an MSM laser microscope (Tibotec, Beerse, Belgium). EC50 was defined as the 50% inhibitory concentration for GFP expression. In parallel, compounds were incubated for three days in a set of white 96-well microtiter plates (Corning) and the cytotoxicity of compounds on HeLa cells was determined by measuring the ATP content of the cells using the ATPlite kit (PerkinElmer, Zaventem , Belgium) according to the manufacturer's instructions. CC50 was defined as the 50% concentration for cytotoxicity. SI is calculated as CC50/EC50. References Hallak LK, Spillmann D, Collins PL, Peeples ME. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J. Virol. 740, 10508-10513 (2000).

权利要求:
Claims (18)
[0001]
1. Compound, characterized by the fact that it presents the Formula (RI),
[0002]
2. A compound of formula (I) according to claim 1, or any stereoisomeric form thereof, characterized in that Het is a heterocycle of any one of the following formulas (a), (b), (c), ( d):
[0003]
3. A compound according to claim 2, characterized in that R23 is selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6-R24 alkyl, SO2R24, SO2N(R24)2 , aryl, heteroaryl, C(=O)OR24, OR24, C(=O)R24, C(=O)N(R24)2, OC(=O)N(R24 )2 and a ring saturated with 4 to 6 members containing an oxygen atom, wherein any such C1-C6 alkyl, C3-C7 cycloalkyl, aryl or heteroaryl is optionally substituted by one or more of the substituents selected from the group consisting of halogen, OH, CN, OCH3; R24 is selected from the group of hydrogen, OH, halogen, C1-C6 alkyl, C3-C7 cycloalkyl, C(=O) C1-C6 alkyl, C(=O) C3-C7 cycloalkyl, aryl, heteroaryl, benzyl, and a saturated 4- to 6-membered ring containing an oxygen atom, wherein any of such C1-C6 alkyl, C3-C7 cycloalkyl, C(=O) C1-C6 alkyl, C(=O) C3-C7 cycloalkyl, aryl , heteroaryl, benzyl is optionally substituted by one or more of the substituents selected from the group consisting of halogen, CF3, OH, CN, OCH3, and OC(=O)CH3.
[0004]
4. Compound of formula (RI) according to claim 1, characterized in that Het is represented by the formula (a'), (b'), (c') or (d'):
[0005]
Compound according to any one of claims 1 to 4, characterized in that, for Formulas (b') and (d'), an X is N.
[0006]
A compound according to any one of claims 1 to 5, characterized in that each of R1a, R1b, R1c or R1d is independently selected from the group consisting of H and halogen.
[0007]
A compound according to any one of claims 1 to 6, characterized in that each of R1a, R1b, R1c or R1d is independently selected from the group consisting of chlorine, bromine and fluorine.
[0008]
8. Compound according to claim 4, characterized in that each of R1a, R1b, R1c or R1d is chlorine.
[0009]
A compound according to any one of claims 1 to 8, characterized in that R2 is -(CR8R9)m-R10 and wherein m is an integer from 1 to 4 and each R8 and R9 is independently selected from H or C1-C6 alkyl.
[0010]
Compound according to any one of claims 1 to 9, characterized in that R2 is C1-C6-R10 alkyl.
[0011]
A compound according to any one of claims 1 to 10, characterized in that R10 is selected from the group consisting of C1-C3-alkyl, H, OH, CN, F, CF2H, CF3, SO2-C1-alkyl C3 and SO2cycloalkyl C3-C6.
[0012]
A compound according to any one of claims 1 to 11, characterized in that the compound has Formula RII, RIII, RIV, RV, RVI or RVII;
[0013]
13. A compound according to claim 12, characterized in that R23 is selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C1-C3 alkyl-R24, SO2R24, O-R24, phenyl, pyridinyl, pyrimidyl, pyrazolyl, C(=O)OR24, C(=O)R24, wherein any such C1-C6 alkyl, phenyl, pyridinyl, pyrimidyl, pyrazolyl is optionally substituted by one or more of the following substituents; OCH3, halogen, OH or CN.
[0014]
14. Compound according to claim 1, characterized in that the compound is
[0015]
A compound according to any one of claims 1 to 14, characterized in that it is for use as a medicament.
[0016]
16. Pharmaceutical composition, characterized in that it comprises a pharmaceutically acceptable carrier, and as an active ingredient a therapeutically effective amount of a compound as defined in any one of claims 1 to 14.
[0017]
A compound according to any one of claims 1 to 14, or a pharmaceutical composition according to claim 15, characterized in that it is for use in the treatment of a respiratory syncytial virus infection.
[0018]
18. Use of a compound as defined in any one of claims 1 to 14, characterized in that it is for the manufacture of a medicament for the treatment of viral infections by RSV.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112015008325B1|2022-01-25|Antiviral compounds against rsv, their use and pharmaceutical composition comprising them

---

PT2651903E|2016-06-17|Benzimidazole respiratory syncytial virus inhibitors

---

KR102092612B1|2020-03-25|1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents

---

AU2013276521A1|2014-12-04|1,3 -dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents

---

ES2669995T3|2018-05-29|Spirourea compounds as antiviral compounds for RSV

---

KR20150032329A|2015-03-25|Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection

---

ES2616784T3|2017-06-14|Quinoxalinones and dihydroquinoxalinones as antiviral agents against respiratory syncytial virus

---

BR112013011949B1|2021-11-23|INDOLS, THEIR USE AS ANTIVIRAL AGENTS OF THE RESPIRATORY SYNCYCIAL VIRUS, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND PROCESSES TO PREPARE THEM

同族专利:

---

公开号 | 公开日

---

LT2909195T|2017-09-25|

---

US20150259367A1|2015-09-17|

---

AU2013334001A1|2015-04-02|

---

EA026628B1|2017-04-28|

---

EA201590748A1|2015-07-30|

---

MX2015004787A|2015-08-14|

---

MY172021A|2019-11-12|

---

HUE033476T2|2017-12-28|

---

PL2909195T3|2017-12-29|

---

EP2909195A1|2015-08-26|

---

DK2909195T3|2017-09-25|

---

PE20150723A1|2015-05-15|

---

US9617289B2|2017-04-11|

---

CL2015000925A1|2015-08-28|

---

ECSP15014941A|2016-01-29|

---

CY1119566T1|2018-03-07|

---

SI2909195T1|2017-10-30|

---

EP2909195B1|2017-06-14|

---

CN104903313B|2017-12-29|

---

KR102280918B1|2021-07-23|

---

SG11201503025WA|2015-06-29|

---

WO2014060411A1|2014-04-24|

---

JP6375300B2|2018-08-15|

---

ZA201502532B|2017-11-29|

---

SA515360258B1|2016-07-16|

---

CA2884491C|2021-08-31|

---

NZ705759A|2019-01-25|

---

CN104903313A|2015-09-09|

---

ME02835B|2018-01-20|

---

TWI598351B|2017-09-11|

---

MX363717B|2019-03-29|

---

KR20150070168A|2015-06-24|

---

TW201427983A|2014-07-16|

---

JP2015534966A|2015-12-07|

---

UA114531C2|2017-06-26|

---

BR112015008325A2|2017-07-04|

---

HK1210462A1|2016-04-22|

---

PT2909195T|2017-09-13|

---

IL237857A|2017-02-28|

---

CA2884491A1|2014-04-24|

---

AR093020A1|2015-05-13|

---

PH12015500780A1|2015-06-15|

---

PH12015500780B1|2015-06-15|

---

ES2640446T3|2017-11-03|

---

HRP20171351T1|2017-11-03|

---

AU2013334001B2|2017-07-20|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US6489338B2|2000-06-13|2002-12-03|Bristol-Myers Squibb Company|Imidazopyridine and imidazopyrimidine antiviral agents|

---

US6506738B1|2000-09-27|2003-01-14|Bristol-Myers Squibb Company|Benzimidazolone antiviral agents|

---

AR043692A1|2003-02-06|2005-08-10|Novartis Ag|2-CYANOPIRROLOPIRIMIDINAS AND ITS PHARMACEUTICAL USES|

---

GB0304640D0|2003-02-28|2003-04-02|Novartis Ag|Organic compounds|

---

TWI515187B|2010-12-16|2016-01-01|健生科學愛爾蘭無限公司|Indoles as respiratory syncytial virus antiviral agents|

---

TWI530495B|2010-12-16|2016-04-21|健生科學愛爾蘭無限公司|Benzimidazole respiratory syncytial virus inhibitors|

---

TWI541241B|2010-12-16|2016-07-11|健生科學愛爾蘭無限公司|Imidazopyridines as respiratory syncytial virus antiviral agents|

---

TWI527814B|2010-12-16|2016-04-01|健生科學愛爾蘭無限公司|Azabenzimidazoles as respiratory syncytial virus antiviral agents|

---

TWI501967B|2010-12-16|2015-10-01|Janssen R&D Ireland|Azaindoles as respiratory syncytial virus antiviral agents|

---

GB201119538D0|2011-11-10|2011-12-21|Viral Ltd|Pharmaceutical compounds|TWI501967B|2010-12-16|2015-10-01|Janssen R&D Ireland|Azaindoles as respiratory syncytial virus antiviral agents|

---

TWI527814B|2010-12-16|2016-04-01|健生科學愛爾蘭無限公司|Azabenzimidazoles as respiratory syncytial virus antiviral agents|

---

TWI515187B|2010-12-16|2016-01-01|健生科學愛爾蘭無限公司|Indoles as respiratory syncytial virus antiviral agents|

---

ES2640916T3|2012-04-26|2017-11-07|Bristol-Myers Squibb Company|Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 inhibitorsto treat platelet aggregation|

---

TWI568722B|2012-06-15|2017-02-01|葛蘭馬克製藥公司|Triazolone compounds as mpges-1 inhibitors|

---

PT2864323T|2012-06-15|2017-07-14|Janssen Sciences Ireland Uc|1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents|

---

WO2014110574A1|2013-01-14|2014-07-17|Incyte Corporation|Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors|

---

MX2015009057A|2013-01-15|2015-10-05|Incyte Corp|Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors.|

---

CN105392787B|2013-05-14|2017-11-24|豪夫迈·罗氏有限公司|For treating and preventing the azepine oxindole of respiratory syncytial virus infection|

---

WO2014184163A1|2013-05-14|2014-11-20|F. Hoffmann-La Roche Ag|Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection|

---

EP3033341B1|2013-08-12|2017-05-03|F.Hoffmann-La Roche Ag|Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection|

---

CA2914541A1|2013-08-15|2015-02-19|F. Hoffmann-La Roche Ag|Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection|

---

MX2016002367A|2013-08-23|2016-10-28|Incyte Corp|Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors.|

---

CN105793265B|2013-12-10|2018-02-13|山东丹红制药有限公司|Imdazole derivatives and its pharmaceutical applications as antivirotic|

---

TWI671299B|2014-04-14|2019-09-11|愛爾蘭商健生科學愛爾蘭無限公司|Spiro urea compounds as rsv antiviral compounds|

---

US9580418B2|2014-07-14|2017-02-28|Incyte Corporation|Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors|

---

US9822124B2|2014-07-14|2017-11-21|Incyte Corporation|Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors|

---

GB201417707D0|2014-10-07|2014-11-19|Viral Ltd|Pharmaceutical compounds|

---

WO2016196244A1|2015-05-29|2016-12-08|Incyte Corporation|Pyridineamine compounds useful as pim kinase inhibitors|

---

EP3305790B1|2015-06-08|2020-08-05|Shangdong Danhong Pharmaceutical Co., Ltd.|Method for preparing imidazole derivative and intermediate thereof and crystal form|

---

CN108200760A|2015-07-22|2018-06-22|英安塔制药有限公司|Benzodiazepinederivatives as RSV inhibitor|

---

TWI734699B|2015-09-09|2021-08-01|美商英塞特公司|Salts of a pim kinase inhibitor|

---

TW201718546A|2015-10-02|2017-06-01|英塞特公司|Heterocyclic compounds useful as PIM kinase inhibitors|

---

ES2882671T3|2015-11-27|2021-12-02|Janssen Sciences Ireland Unlimited Co|Heterocyclic indoles for use in influenza virus infections|

---

WO2017123884A1|2016-01-15|2017-07-20|Enanta Pharmaceuticals, Inc.|Heterocyclic compounds as rsv inhibitors|

---

BR112018014794A2|2016-01-20|2018-12-11|Janssen Sciences Ireland Uc|aryl substituted pyrimidines for use in influenza virus infection|

---

EP3414247B1|2016-02-08|2021-04-21|F. Hoffmann-La Roche AG|Spiroindolinones as ddr1 inhibitors|

---

WO2018025043A1|2016-08-04|2018-02-08|ReViral Limited|Pyrimidine derivatives and their use in treating or preventing a respiratory syncytial virus infection|

---

WO2018038668A1|2016-08-25|2018-03-01|Medivir Ab|Respiratory syncytial virus inhibitors|

---

WO2018038667A1|2016-08-25|2018-03-01|Medivir Ab|Respiratory syncytial virus inhibitors|

---

RU2019128300A3|2017-02-16|2021-06-25|

---

WO2019006295A1|2017-06-30|2019-01-03|Enanta Pharmaceuticals, Inc.|Heterocyclic compounds as rsv inhibitors|

---

GB201711704D0|2017-07-20|2017-09-06|Reviral Ltd|Pharmaceutical compounds|

---

CN107383011B|2017-08-01|2019-05-10|深圳百奥捷生物科技有限公司|A kind of antiviral alkaloid and preparation method thereof being isolated from Folium Forsythia radix scutellariae|

---

CN107253951B|2017-08-01|2019-05-10|深圳百奥捷生物科技有限公司|A kind of purine alkaloid and its application as anti-RSV virus drugs|

---

CN109369658B|2017-08-08|2020-01-31|沈阳药科大学|Synthesis method of spiro [ pyrrolidine-3, 3' -oxindole ] ring systems|

---

WO2019113487A1|2017-12-08|2019-06-13|Incyte Corporation|Low dose combination therapy for treatment of myeloproliferative neoplasms|

---

US11066404B2|2018-10-11|2021-07-20|Incyte Corporation|Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors|

---

CA3133300A1|2019-03-18|2020-09-24|Enanta Pharmaceuticals, Inc.|Benzodiazepine derivatives as rsv inhibitors|

---

WO2021050612A1|2019-09-09|2021-03-18|Cidara Therapeutics, Inc.|Compositions and methods for the treatment of respiratory syncytial virus|

---

WO2021098732A1|2019-11-18|2021-05-27|江苏恩华药业股份有限公司|1',2'-dihydro-3'h-spiro[cyclobutane 1,4'-isoquinoline]-3'-one derivative and application thereof|

法律状态:
2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2019-05-21| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-09-10| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-08-10| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2021-11-16| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2022-01-25| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/2013, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP12188694.9|2012-10-16|

---

EP12188694|2012-10-16|

---

EP13159431|2013-03-15|

---

EP13159431.9|2013-03-15|

---

PCT/EP2013/071525|WO2014060411A1|2012-10-16|2013-10-15|Rsv antiviral compounds|

---